{"Title": ["Why the FDA's Drug Competition Action Plan Is Bad News for Generic Pharmaceutical Stocks", "ANI Pharmaceuticals Inc (ANIP) Q1 2020 Earnings Call Transcript", "ANI Pharmaceuticals Q1 20 Earnings Conference Call At 10:30 AM ET", "ANI Pharma Suspends Guidance; Appoints Patrick Walsh As Interim President & CEO", "ANI Pharmaceuticals, Inc. Q1 adjusted earnings Beat Estimates", "ANI Gets Refusal To File Letter For Cortrophin Gel; Seeks Meeting With FDA", "How ANI Pharmaceuticals Plans to Take Down a Price-Gouging Giant", "Notable Wednesday Option Activity: QCOM, NOW, ANIP", "Why the FDA's Drug Competition Action Plan Is Bad News for Generic Pharmaceutical Stocks", "ANI Pharma Launches Omega-3-Acid Ethyl Esters Capsules - Quick Facts", "ANI Pharmaceuticals Inc (ANIP) Q4 2019 Earnings Call Transcript", "ANI Pharmaceuticals Q4 19 Earnings Conference Call At 10:30 AM ET", "ANI Pharma Guides FY20 Below Estimates - Quick Facts", "ANI Pharmaceuticals, Inc. Q4 adjusted earnings Miss Estimates", "ANI Pharma Launches Sulfamethoxazole & Trimethoprim Oral Suspension", "Commit To Buy ANI Pharmaceuticals At $55, Earn 13% Annualized Using Options", "ANI Pharmaceuticals CEO Arthur Przybyl To Depart On May 10 - Quick Facts", "ANI Pharma Acquires U.S. Portfolio Of 23 Generic Products From Amerigen", "ANI Pharma To Present At Evercore ISI HealthCONx Conference; Webcast At 10:15 AM", "ANI Pharmaceuticals, Inc. Q3 adjusted earnings Miss Estimates", "ANI Pharma Reports Positive Results From Cortrophin Gel Cortisol Response Study", "ANI Pharmaceuticals Inc (ANIP) Q2 2019 Earnings Call Transcript", "ANI Pharmaceuticals is Now Oversold (ANIP)", "ANI Pharmaceuticals, Inc. Q2 adjusted earnings Beat Estimates", "ANI Pharma : FDA Okays Potassium Citrate Extended-Release Tablets USP", "ANI Pharmaceuticals Q1 19 Earnings Conference Call At 10:30 AM ET", "ANI Pharmaceuticals, Inc. Q1 adjusted earnings Beat Estimates", "Commit To Purchase ANI Pharmaceuticals At $60, Earn 8.1% Annualized Using Options", "ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: What You Should Know", "Ultragenyx's (RARE) UX007 Gets Fast Track Status by FDA", "ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know", "ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: What You Should Know", "ANI Pharmaceuticals Inc (ANIP) Q1 2019 Earnings Call Transcript", "3 Under-the-Radar Value Stocks to Buy in 2019", "3 Top Small-Cap Stocks to Buy Right Now", "Is ANI Pharmaceuticals a Great Stock for Value Investors?", "ANI Pharmaceuticals Inc (ANIP) Q3 2018 Earnings Conference Call Transcript", "Zacks Industry Outlook Highlights: Amgen, ANI and Illumina", "Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval", "Sarepta's DMD Portfolio Solid, Sole Drug Dependence Concerns", "ANI Pharmaceuticals (ANIP) Q4 2018 Earnings Conference Call Transcript", "Juniper Inks Deal to be Acquired by Catalent, Shares Up", "Alkermes' Aristada Initio Approved by FDA for Schizophrenia", "Roche's Breast Cancer Study Meets Co-Primary Endpoint", "Keryx (KERX) Inks Merger Deal With Akebia, Shares Fall", "Celgene's Luspatercept Meets Primary Endpoint in the Study", "Jazz Pharmaceuticals' sNDA for Xyrem Gets Priority Review", "Medicines Company's Inclisiran Studies to Continue Unmodified", "Biotech Stock Outlook: Short-Term Pricing Pain to Prevail", "Lilly's Diabetes Drugs Meet Endpoints in Phase III Studies", "Roche's (RHHBY) Flu Candidate Gets Priority Review by the FDA", "Pfizer's Breast Cancer Drug Misses Overall Survival in Study", "Merrimack Crashes as Phase II Pancreatic Cancer Study Fails", "Novo Nordisk (NVO) Announces Results in Diabetes Studies", "Anika Reports Top Line Data from CINGAL Study, Shares Slump", "Puma Biotechnology's Shares Rise on Positive CHMP Trend Vote", "Alexion (ALXN) Submits Application for ALXN1210 with FDA", "Agios (AGIO) Initiates Phase III Study on PK Deficiency Drug", "Roche to Buy Rest of Foundation Medicine for $2.4 billion", "4 Undervalued MedTech Stocks to Consider Amid Volatility", "4 Undervalued MedTech Stocks to Consider Amid Volatility", "Sarepta Inks Manufacturing Deal for Gene Therapy Program", "Flex Pharma Down on Workforce Reduction, Ends Phase II Study", "Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs", "Alexion (ALXN) Submits Application for ALXN1210 with FDA", "Ligand Pharmaceuticals (LGND) Hits a 52-Week High, Can the Run Continue?", "Should Value Investors Pick ANI Pharmaceuticals (ANIP) Stock?", "Mylan Trying To Close In On Key Technical Measure", "Perrigo Clears Key Benchmark, Hitting 80-Plus RS Rating", "How Hospitals Plan To Put Pressure On Generic-Drug Makers", "Here's Why Sarepta is Up More Than 60% So Far This Year", "BioMarin's Palynziq Gets FDA Approval for Phenylketonuria", "INSYS Gets Negative FDA Recommendation for Pain Candidate", "Ligand Pharmaceuticals (LGND) Hits a 52-Week High, Can the Run Continue?", "Stocks Generating Improved Relative Strength: Lannett", "Stocks Showing Rising Market Leadership: Insys Therapeutics Earns 89 RS Rating", "Top-Rated Stocks: ANI Pharmaceuticals Sees Composite Rating Climb To 97", "Perrigo Getting Closer To Key Technical Benchmark", "Mylan Hits 80-Plus Relative Strength Rating Benchmark", "Perrigo Trying To Close In On Key Technical Benchmark", "Stocks To Watch: ANI Pharmaceuticals Sees Relative Strength Rating Rise To 93", "Spectrum Doubles in 3 Months: What's Driving the Rally?", "ANI Pharmaceuticals (ANIP) Catches Eye: Stock Jumps 17.7%", "Stocks Showing Market Leadership: Collegium Pharmaceutical Earns 91 RS Rating", "Taro Pharmaceutical Industries Earns RS Rating Upgrade", "Pfizer Hikes Dividend, Announces $10B Share Buyback Plan", "Perrigo Gets Technical Rating Upgrade", "3 Small, Profitable Biotechs With Fantastic Growth", "ANIP Crosses Above Average Analyst Target", "Perrigo Sees IBD RS Rating Improve To 73", "3 Top Small-Cap Stocks to Buy in August", "4 Top Small-Cap Stocks to Buy in June", "4 of the Cheapest Biotech Stocks in the World", "Lannett Joins Elite Club Of Stocks With RS Ratings Over 90", "Pre-Market Earnings Report for March 2, 2017 : CNQ, KR, BUD, BURL, JOY, ACIW, MEI, ANF, DEA, BKS, ANIP, SUP", "4 Top Small-Cap Stocks to Buy This Winter", "5 Growth Stocks That Could Double", "Thursday Sector Laggards: Music & Electronics Stores, Drugs", "Ocular Begins Enrollment in Phase III Trial on Glaucoma Drug", "The Zacks Analyst Blog Highlights: VIVUS, Geron, Achillion Pharmaceuticals, Anika Therapeutics and ANI Pharmaceuticals", "Teva Boosts Generic Business with Allergan Anda Takeover", "Moving Average Crossover Alert: ANI Pharmaceuticals (ANIP)", "AbbVie: HCV Regimen Obtains Breakthrough Therapy Status", "ImmunoGen to Cut Workforce by 17% for Long Term Growth", "Endo International Reports Positive Phase II Data on Xiaflex", "Pain Therapeutics (PTIE) Down on CRL for Chronic Pain Drug", "Jazz Pharma Closes Enrollment in OSA Drug Phase III Trial", "AcelRx (ACRX) Initiates Phase III IAP312 Study on Zalviso", "Juno Therapeutics (JUNO) Catches Eye: Stock Jumps 13%", "VIVUS Licenses Stendra Rights to Metuchen Pharmaceuticals", "AbbVie (ABBV) Files sNDA for Blood Cancer Drug Imbruvica", "Amarin Corporation (AMRN) Looks Good: Stock Adds 6.1% in Session", "Achillion, J&J HCV Triple Combination Drug Data Presented", "AbbVie (ABBV) HCV Combination Drug Positive in Phase IIIb", "Strength Seen in NewLink Genetics (NLNK): Stock Jumps 5%", "BioTime (BTX) Shows Strength: Stock Adds 5.9% in Session", "Ligand Inks CNS License Agreement with Seelos Therapeutics", "Amgen's Multiple Myeloma Drug Kyprolis Fails in Phase III", "AstraZeneca Withdraws Cediranib Marketing Application in EU", "The Medicines Co. to Get BARDA Funding for Infection Drugs", "Dicerna Pharmaceuticals (DRNA) Worth a Look: Stock Up 6%", "Puma (PBYI) Neratinib's NDA Accepted for Review, Stock Up", "Amgen (AMGN) Repatha Meets Endpoints in Phase III Study", "Bristol-Myers Opdivo's Regulatory Application Validated in EU", "Adamas (ADMS) Parkinson's Disease Drug Positive in Phase III", "Zacks.com featured highlights: ANI Pharmaceuticals, Stoneridge, Cooper-Standard Holdings, Amkor Technology and Companhia de Saneamento Basico do Estado de Sao Paulo", "Regenxbio (RGNX) Worth Watching: Stock Adds 5.3% in Session", "Regeneron, Teva Collaborate to Develop Chronic Pain Drug", "BioDelivery Bunavail Gets Better Managed Care Positioning", "Sarepta Stock Nearly Doubles on FDA Approval for DMD Drug", "Bayer (BAYRY) Strives for Increased Sales & Earnings Growth", "Cara Therapeutics (CARA) Catches Eye: Stock Rises 5.7%", "CoLucid Pharmaceuticals (CLCD) in Focus: Stock Jumps 7.4%", "ProQR Therapeutics (PRQR) Catches Eye: Stock Rises 8.2%", "Celgene Presents Efficacy & Safety Phase II Ozanimod Data", "Vical Slumps, Cytomegalovirus Vaccine Fails in Phase II Study", "Amgen (AMGN) Parsabiv Gets Positive CHMP Opinion in EU", "AstraZeneca Diabetes Drug Combination Positive in Phase III", "Ligand (LGND) Inks Deal with TeneoBio for OmniAb Technology", "Eli Lilly (LLY) Gets Favorable CHMP Opinion for Olaratumab", "Novartis (NVS) Presents Positive Data on Cardiovascular Drug", "Idera Pharmaceuticals in Focus: Stock Adds 8.8% in Session", "Masimo PVI: Efficient Predictor for Fluid Optimization", "Qiagen: Molecular Diagnostics & Expansion Plans on Track", "Novavax Tanks, RSV F Vaccine Disappoints in Two Studies", "Merck/Pfizer Diabetes Drug Ertugliflozin Positive in Phase III", "Teva/Intel Tie up for Huntington's Disease Technology Platform", "Glaxo (GSK) Publishes Phase III Data on Shingles Vaccine", "Novo Nordisk (NVO) Presents Data on Obesity Drug Saxenda", "Halozyme Therapeutics (HALO) Catches Eye: Stock Up 7.9%", "Bayer to Boost Agriculture Suite with $66B Monsanto Buyout", "Aerie (AERI) Stock Up on Positive Phase III Data on Roclatan", "Shire's Immunodeficiency Treatment Cuvitru Gets FDA Approval", "Asterias Biotherapeutics (AST) Catches Eye: Stock Jumps 6%", "Allergan to Buy Vitae Pharma to Boost Dermatology Suite", "Spectrum (SPPI) Down, Qapzola Fails to Impress FDA Panel", "Sarepta Shares Soar on News of Key Drug Critic FDA Exit", "Roche Ocrevus Positive in Phase III Multiple Sclerosis Trials", "ANI Pharmaceuticals (ANIP) Sees Hammer Chart Pattern; Time to Buy?", "The Zacks Analyst Blog Highlights: Mylan, ANI Pharmaceuticals, Cambrex, PDL BioPharma and Innoviva", "Ligand (LGND) Commences Phase II Type II Diabetes Study", "Sanofi (SNY) Presents Positive Diabetes Data on iGlarLixi", "Will Bayer (BAYRY) Raise its Monsanto Buyout Offer Again?", "Glaxo/J&J File for Rheumatoid Arthritis Drug Sirukumab in EU", "Geron (GERN) at 52-Week Low on Imetelstat Study Update", "Sanofi (SNY) Presents Positive Diabetes Data on iGlarLixi (revised)", "Celgene's Crohn's Disease Drug Positive in Phase Ib Study", "Reata Pharmaceuticals (RETA) Jumps: Stock Rises 13.2%", "4 Biotech Stocks to Buy as Election Fever Rises", "Xencor (XNCR) Doses First Patient in Myeloid Leukemia Trial", "Tesaro Gets Fast Track Designation for Ovarian Cancer Drug", "Auris (EARS) Advances on Sudden Deafness Study, Stock Up", "Achillion, J&J's HCV Combo Drug Positive in Phase IIa Trial", "Repros Seeks EU Approval for Secondary Hypogonadism Drug", "bluebird bio Stock Up on Start of Phase III LentiGlobin Study", "Epizyme Non-Hodgkin Lymphoma Drug Clears Futility Hurdle", "Alnylam (ALNY) Reports Positive Phase I Data on ALN-AS1", "Repros Therapeutics' (RPRX) Proellex Positive in Phase II", "Dynavax Rebounds on Same PDUFA Date for Heplisav BLA", "CoLucid Hits 52 Week High on Positive Data on Migraine Drug", "Exelixis Reports Interim Analysis of Liver Cancer Trial Data", "Asterias Biotherapeutics (AST) Soars: Stock Rises by 10.9%", "Masimo Amends Nellcor's Pulse Oximetry Royalty Agreement", "Novartis (NVS) Reports Positive Data on Ultibro Breezhaler", "Bayer (BAYRY) Raises Offer to Purchase Monsanto Yet Again", "Catalyst Firdapse Gets Orphan Status for Myasthenia Gravis", "Astrazeneca (AZN) Presents Benralizumab Phase III Data", "Compugen (CGEN) Looks Good: Stock Adds 5.1% in Session", "Myriad Genetics Adds Assurex Health, Grows in Neuroscience", "Glaxo Bexsero Meningitis B Immunization Shows Positive Data", "Novo Nordisk's IDegLira Review Period Extended in the U.S.", "Merck Stops Development of Odanacatib for Osteoporosis", "Mylan (MYL) Gets Positive Copaxone USPTO Ruling Yet Again", "Arena (ARNA) Beacon Discovery to Boost Research Platform", "Amgen Gets FDA Approval for Label Expansion of Blincyto", "Roche Immuno-oncology Drug Tecentriq Positive in Phase III", "Amarin (AMRN) Ends Patient Randomization in Vascepa Study", "Mylan's EpiPen Misclassified, Rebates Underpaid; Stock Down", "Pfizer's Lung Cancer Drug Xalkori Label Expanded in the EU", "Array (ARRY) Presents Positive Cardiovascular Trial Data", "Express Scripts' New Program to Lower Diabetes Care Costs", "ARIAD Finishes Rolling NDA for Lung Cancer Drug Brigatinib", "Orexigen Stock Up on Commercialization Deal for Contrave", "Rigel (RIGL) Stock Up on Positive Phase III Fostamatinib Data", "CoLucid Pharmaceuticals (CLCD) Jumps: Stock Rises 12.1%", "What Makes Editas Medicine (EDIT) a Strong Sell?", "Alexion's GVHD Candidate Gets Orphan Drug Status in the EU", "Amgen (AMGN) Reports Positive Data on Prolia and Repatha", "Inovio Stock Up as Second Zika Virus Vaccine Study Begins", "Macrocure Stock Up on Merger Deal with Leap Therapeutics", "This Week's Hidden Gems: (AMWD)(ANIP)", "Regeneron/Sanofi Present Positive Phase III Praluent Data", "Roche Gets FDA Nod for Emergency Use of Zika Virus Test", "CTI BioPharma Reports Mixed Pacritinib Study Data, Stock Up", "Mallinckrodt DMD Drug Gets Fast Track Status in the U.S.", "Vanda Stock Up on Favorable U.S. Court Ruling for Fanapt", "Mylan (MYL) Obtains Favorable USPTO Ruling for Copaxone", "Amgen Gets CRL for Secondary Hyperparathyroidism Drug", "Kindred Biosciences (KIN) Jumps: Stock Moves 5.7% Higher", "Urban Outfitters, Fogo de Chao, Oclaro, ANI Pharmaceuticals and FormFactor highlighted as Zacks Bull and Bear of the Day", "Mylan (MYL) Draws Flak for Over Pricing EpiPen, Stock Down", "Abbott Labs Sued by Alere over Pending $5.8B Acquisition", "Mallinckrodt DMD Drug Gets Fast Track Status in the U.S.", "Vanda Stock Up on Favorable U.S. Court Ruling for Fanapt", "Roche Launches Accu-Chek Blood Glucose Monitoring System", "Galapagos (GLPG) Advances RA Drug Filgotinib to Phase III", "Puma (PBYI) Neratinib's Application Validated in EU, Stock Up", "Zacks.com featured highlights: ANI Pharmaceuticals, Cooper-Standard Holdings, Berry Plastics Group, Amkor Technology and Power Integrations", "3 Small-Cap Stocks With Sky-High Growth Potential", "Pfizer to Acquire Rights to AstraZeneca's Antibiotics Business", "Editas Medicine (EDIT) in Focus: Stock Moves 5.1% Higher", "Xenetic's IND to Start Phase II Virexxa Study Accepted in U.S.", "Portola IndexXa's Regulatory Application Validated in the EU", "Pfizer's (PFE) Pain Drug Troxyca ER Receives FDA Approval", "Horizon (HZNP) Rayos Receives USPTO Notice of Allowance", "Aclaris (ACRS) Common Warts Candidate Positive in Phase II", "FDA OKs Edwards Lifesciences' Sapien 3 for Extended Use", "Supernus' Trokendi XR Gets FDA Nod for Migraine in Adults", "Intercept (ICPT) Ocaliva Phase III POISE Data Published", "Cerulean (CERU) Kidney Cancer Drug Disappoints in Phase II", "Why ANI Pharmaceuticals (ANIP) Could Be Positioned for a Surge?", "Sunesis Pharmaceuticals (SNSS) Jumps: Stock Rises 23.1%", "OncoGenex Down on Poor Phase III Data on Lead Cancer Drug", "How ANI Pharmaceuticals (ANIP) Stock Stands Out in a Strong Industry", "Actelion (ALIOF) Uptravi Approved for PAH in Switzerland", "Portola (PTLA) Stock Down on CRL for AndexXa BLA in U.S.", "Inovio (INO) Veterinary Vaccine Rights Licensed to Plumbline", "Radius (RDUS) Osteoporosis Drug Positive in Phase III Study", "Align Technology's Invisalign Dependence: Boon or Curse?", "FDA Approves Edwards Lifesciences' Intuity Elite Heart Valve", "Aurinia (AUPH) Stock Falls on Poor Phase II Lupus Study Data", "Can The Uptrend Continue for ANI Pharmaceuticals (ANIP)?", "Repros Presents 6-Month Interim Data on Enclomiphene", "Syros Pharmaceuticals (SYRS) Jumps: Stock Moves Up 36.1%", "Vertex (VRTX) To Stop VX-661-Ivacaftor Study, Stock Down", "Myriad Genetics: Q4 Hit by Low Test Revenues, Gross Margin", "Bristol-Myers to Reacquire Rights to Oncology Drug in Asia", "Myriad Genetics (MYGN) in Focus: Stock Up 5.6% in Session", "3 Reasons Why ANI Pharmaceuticals (ANIP) is a Great Momentum Stock", "Strongbridge Biopharma (SBBP) Jumps: Stock Moves Up 5.5%", "Perrigo (PRGO) Misses Q2 Earnings Estimates, Cuts '16 View", "UCB Epilepsy Drug Vimpat's Patent Validated by U.S. Court", "Catalyst (CPRX) Reports Narrower-than-Expected Q2 Loss", "Mylan Beats on Q2 Earnings, Revenues Miss, Keeps '16 View", "Intrexon (XON) Reports Wider Loss in Q2, Revenues Increase", "Aegerion (AEGR) Q2 Loss Wider than Expected, View Intact", "GW Pharma (GWPH) Incurs Narrower-than-Expected Q3 Loss", "Endo (ENDP) Tops Q2 Earnings Estimates, Keeps 2016 View", "Fate Therapeutics (FATE) Jumps: Stock Moves 22.8% Higher", "Puma (PBYI) Posts Narrower Loss in Q2, Focus on Neratinib", "Celldex (CLDX) Posts Narrower Q2 Loss, Focus on Pipeline", "3 Top Ranked Growth Stocks to Buy this Year", "Horizon (HZNP) Earnings Up Y/Y, Keeps '16 View, Stock Up", "ANI Pharmaceuticals (ANIP) Shares March Higher, Can It Continue?", "ANI Pharmaceuticals (ANIP) Catches Eye: Stock Jumps 6.9%", "Conatus (CNAT) Posts Narrower Q2 Loss, Emricasan in Focus", "Regeneron (REGN) Tops Q2 Earnings, Keeps '16 Eylea View", "Arena's (ARNA) Q2 Loss Narrower, Revenues Increase Y/Y", "Aerie (AERI) Q2 Loss Wider than Expected, Pipeline in Focus", "Zoetis (ZTS) Beats on Q2 Earnings & Revenues, Lifts Outlook", "Prothena (PRTA) Reports Wider-than-Anticipated Loss in Q2", "What's in the Cards for TripAdvisor (TRIP) in Q2 Earnings?", "Nivalis (NVLS) Reports Wider-than-Expected Loss in Q2", "Humana (HUM) May Beat Q2 Earnings: Will the Stock Gain?", "Keryx (KERX) Stock Down on Wider Q2 Loss, Supply Issues", "Geron (GERN) Posts Narrower-Than-Expected Loss in Q2", "Penumbra (PEN) to Report Q2 Earnings: What's in the Cards?", "GoDaddy (GDDY) Q2 Earnings Likely to Beat: Stock to Gain?", "Can DENTSPLY (XRAY) Spring an Earnings Surprise in Q2?", "Will TrovaGene (TROV) Pull an Earnings Surprise in Q2?", "Inogen (INGN) Q2 Earnings: Can the Stock Pull a Surprise?", "Pacific Biosciences (PACB) Q2 Earnings: What's in Store?", "Sanofi (SNY) Posts In-Line Q2 Earnings, Revenues Down Y/Y", "22nd Century Group (XXII) Catches Eye: Stock Rises 7.8%", "Aetna (AET) Poised to Beat on Earnings in Q2: Here's Why", "Alkermes (ALKS) Posts Narrower Q2 Loss, Ups 2016 Outlook", "Agenus (AGEN) Posts Narrower than Expected Loss in Q2", "Can PerkinElmer (PKI) Pull a Surprise this Earnings Season?", "AstraZeneca (AZN) Beats on Q2 Earnings, Keeps 2016 View", "Becton, Dickinson (BDX) Q3 Earnings: What's in the Cards?", "Fate Therapeutics (FATE) Catches Eye: Stock Rises 5.9%", "Integra (IART) Tops Q2 Earnings, Grows Organically, Ups View", "Can Cerner (CERN) Spring a Surprise This Earnings Season?", "Cardinal Health (CAH) Q4 Earnings: Disappointment in Store?", "Celgene (CELG) Tops Q2 Earnings & Revenues, Lifts View", "Alexion (ALXN) Tops Q2 Earnings and Revenues (Revised)", "Glaxo (GSK) Beats Q2 Earnings Estimates, Revenues Up Y/Y", "Bristol-Myers (BMY) Beats on Q2 Earnings, Lifts Outlook", "BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 6.6%", "Eleven Biotherapeutics (EBIO) Jumps: Stock Rises by 10.4%", "Cigna (CI) to Report Q2: Will it Continue to Beat Estimates?", "Vertex (VRTX) Posts Narrower Q2 Loss, Revenues Fall Short", "Curis (CRIS) in Focus: Stock Adds 5.7% in Session", "Eleven Biotherapeutics (EBIO) in Focus: Stock Rises 13%", "After GILD Earnings, Which Biomed Stock is Best Right Now?", "Synta (SNTA) Cuts Q2 Loss Y/Y, Madrigal Merger in Focus", "AVEO Pharmaceuticals (AVEO) Catches Eye: Stock Up 10.4%", "Bayer (BAYRY) Beats on Q2 Earnings, Updates 2016 Outlook", "Ligand Pharmaceuticals (LGND) Jumps: Stock Rises 5.5%", "Bio-Techne (TECH) Set to Acquire Space Import-Export", "Merck to Acquire Brazilian Animal Health Company for $400M", "Alnylam Stock Up on Favorable Patisiran and Revusiran Data", "XBiotech Xilonix Positive in Phase III Colorectal Cancer Study", "Integra LifeSciences at 52-Week High on Solid Q1 Results", "Arena (ARNA) to Cut 73% Workforce, Shifts Focus to Pipeline", "Biogen (BIIB) Stock Up on Q2 Earnings Beat, Raised Outlook", "Ligand Pharmaceuticals (LGND) Jumps: Stock Rises 5.5%", "Bio-Techne (TECH) Set to Acquire Space Import-Export", "Merck to Acquire Brazilian Animal Health Company for $400M", "Two Small-Cap Healthcare Stocks That are Cheap Buys Right Now", "Esperion (ESPR) Offers Updates on LDL-Lowering Candidate", "Endo's Stock Gains on Vasostrict's New Patent Approval", "The Medicines Co.'s Carbavance Scores in Phase III Study", "Bristol-Myers, PsiOxus Strike Immuno-Oncology Collaboration", "GW Pharmaceuticals Stock Up on Positive Epidiolex Data", "Zacks.com featured highlights: John Bean Technologies, ANI Pharmaceuticals, Clearwater Paper, Companhia de Saneamento Basico do Estado de Sao Paulo and Unisys", "XBiotech (XBIT) Catches Eye: Stock Adds 5.6% in Session", "Sanofi Inks Deal to Swap Business with Boehringer Ingelheim", "Genmab/Novartis' Arzerra Gets Unfavorable CHMP Opinion", "Gilead's (GILD) HIV Treatment Odefsey Gains Approval in EU", "5 Stocks to Buy on New Analyst Coverage", "Health Care Sector Update for 06/28/2016: TTPH, ANIP", "Axsome Therapeutics (AXSM) Catches Eye: Stock Jumps 6.6%", "Cascadian Therapeutics (CASC) Jumps: Stock Rises 10.4%", "Retrophin (RTRX) RE-024 Positive in Physician-Initiated Study", "3 Biotech Stocks at Risk From the 2016 U.S. Presidential Election (ANIP ARIA PRTA)", "Incyte Reports Epacadostat Combination Study Initiation", "Nymox (NYMX) Stock Up on Positive 7-Year Fexapotide Data", "Epizyme Teams Up with Roche's Genentech for Tazemetostat", "Proteon Therapeutics (PRTO) in Focus: Stock Gains 6.4%", "Anavex's Lead Candidate Gets Orphan Drug Status Yet Again", "GW Pharma (GWPH) to Develop Epidiolex for Infantile Spasms", "RedHill (RDHL) Stock Up on Positive Phase I Data on Yeliva", "Prima Reports Favorable Initial Breast Cancer Study Data", "Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up", "Gilead Presents Favorable Preliminary Bictegravir HIV Data", "Vical (VICL) Reports Phase I/II Data on Genital Herpes Vaccine", "Pluristem Therapeutics (PSTI) Catches Eye: Stock Up 11.6%", "WAVE Life Sciences (WVE) in Focus: Stock Up 6.1% in Session", "GTx (GTXI) Shows Strength: Stock Adds 11.2% in Session", "Inovio Stock Up, Zika Vaccine Gets Nod for Phase I Study", "Auris (EARS) Begins Phase III Study for Sudden Deafness", "Emergent (EBS) BioThrax sBLA Accepted for FDA Review", "Medivation's (MDVN) Pidilizumab Positive in Phase I/II Study", "Idera Pharmaceuticals (IDRA) Catches Eye: Stock Rises 8.3%", "Sunesis Pharmaceuticals (SNSS) in Focus: Stock Gains 8.7%", "WAVE Life Sciences (WVE) in Focus: Stock Up 6.1% in Session", "Cytokinetics (CYTK) Looks Good: Stock Adds 6.8% in Session", "Jazz Pharmaceuticals Offers HAL Study Data on JZP-110", "Marinus Stock Down on Dismal Phase III Data on Ganaxolone", "Abbott Labs (ABT) Reports Positive Data on FreeStyle Libre", "Pfizer Reveals Final Phase III Data on Inotuzumab Ozogamicin", "Health Care Sector Update for 06/13/2016: JNJ, PFE, ABT, MRK, AMGN, BIOS, ANIP", "Emergent (EBS) BioThrax Gets Orphan Status in the U.S.", "Dimension Therapeutics (DMTX) Jumps: Stock Moves 6.7% Up", "Pfizer's Xeljanz Positive in Active Psoriatic Arthritis Study", "AstraZeneca Presents Tagrisso Leptomeningeal Disease Data", "Alexion's Soliris Misses Phase III Primary Efficacy Endpoint", "Exelixis (EXEL) Shows Strength: Stock Moves 11.2% Higher", "Pfizer (PFE) Presents Data on Utomilumab for Solid Tumors", "Celldex (CLDX) Presents Phase II Melanoma Study Data", "Nexvet Biopharma (NVET) Jumps: Stock Moves 9.2% Higher", "Puma (PBYI) Presents Favorable Phase II Data on Neratinib", "Tobira Therapeutics (TBRA) in Focus: Stock Up 6.4% in Session", "Merck (MRK) Reveals Data from Ongoing Studies on Keytruda", "AstraZeneca Sells Zurampic's EU and Latin American Rights", "Amarin (AMRN) Looks Good: Stock Adds 6.7% in Session", "Alexion's (ALXN) Rare Disorder Drug Gets EU Orphan Status", "AveXis (AVXS) Looks Good: Stock Adds 6.5% in Session", "Regeneron, Sanofi Report Positive Dupilumab Phase III Data", "Regeneron Reports Interim Data on Cholesterol Lowering Drug", "Teva's Huntington Disease Drug Receives CRL from the FDA", "Ultragenyx Pharmaceutical (RARE) Jumps: Stock Up 6.6%", "Vertex (VRTX) Orkambi sNDA Accepted with Priority Review", "Integra (IART): Strong Revenue Growth on Global Prospects", "CoLucid Pharmaceuticals (CLCD) in Focus: Stock Rises 11.1%", "BioMarin Withdraws Kyndrisa Marketing Application in EU", "Nektar (NKTR) Inks Deal With Daiichi Sankyo for Onzeald", "AstraZeneca Reports Positive Phase III Data on Faslodex", "Intercept's (ICPT) Liver Dug Ocaliva Approved by the FDA", "Will ANI Pharmaceuticals (ANIP) Continue to Surge Higher?", "Flexion (FLXN) Zilretta Gets Positive FDA Guidance; Stock Up", "The Medicines Co. Carbavance TANGO 1 Study Enrolled", "Alkermes Begins Phase I Study on Immuno-Oncology Drug", "Innocoll Stock Gains on Favorable Phase III Data on Xaracoll", "Gilead's (GILD) New HCV Drug Epclusa Wins CHMP Backing", "Glaxo/Innoviva Report Positive COPD Data on Relvar Ellipta", "AbbVie/Boehringer Report Crohn's Disease Drug Interim Data", "Biodel/Albireo Limited to Combine; Focus on Liver Diseases", "Zacks.com featured expert Kevin Matras highlights: ANI Pharmaceuticals, KCG Holdings, McDermott International, Powell Industries and Rose Rock Midstream", "Should You Get Rid of AMAG Pharmaceuticals (AMAG) Now?", "Galapagos' RA Drug Filgotinib to Enter Phase III in 3Q16", "Alnylam Pharmaceuticals (ALNY) in Focus: Stock Rises 9.9%", "Baxalta Reports Positive Phase I Study Data on BAX 930", "Pfizer Champix's Label to Include More Data, Warning Lifted", "Integra Unveils Fin-Lock Glenoid, Boosts Shoulder Arthroplasty", "This Value Screen Is Our Top Performer This Year", "Pfizer's (PFE) Trumenba Accepted for Review in the EU", "Dicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 8.7%", "Acorda Shelves Development of Epilepsy Treatment, Plumiaz", "Notable Wednesday Option Activity: ASNA, ANIP, CVX", "Pronai Therapeutics (DNAI) Shows Strength: Stock Rises 7.4%", "ImmunoGen Announces Phase I Cohort Ovarian Cancer Data", "Bristol-Myers Reports Two-Year Overall Survival Opdivo Data", "Glaxo/Innoviva Unveil SUMMIT Study Data on Breo Ellipta", "Agios Strikes Metabolic Immuno-Oncology Deal with Celgene", "Bristol-Myers' Opdivo Wins FDA Nod for Additional Indication", "Nivalis Starts Dosing in Second Phase II Cystic Fibrosis Study", "Horizon (HZNP) to Buy Global Rights to Actimmune, Stock Down", "Pfizer (PFE) Reveals Positive Phase III Data on Trumenba", "Mylan to Buy Renaissance's Topical Business for about $1B", "Bayer Stops Phase II Adempas Study Due to Safety Issues", "Dr. Reddy's (RDY) Q4 Earnings & Revenues Decline Y/Y", "Zacks Investment Ideas feature highlights: Post Holding, Facebook, Paylocity, Ani Pharmaceuticals and AMN Healthcare Services", "Kite Pharma (KITE) Upgraded to Hold on Strong Fundamentals", "Perrigo (PRGO) Tops Q1 Earnings, 2016 Earnings View Intact", "Trevena (TRVN) Down on Negative Phase IIb Data on TRV027", "BioDelivery-Collegium Collaborate for Onsolis in U.S.", "Intrexon (XON) Q1 Loss Wider than Expected, Revenues Miss", "AVEO Q1 Loss In Line with Expectation, Tivozanib in Focus", "Synta (SNTA) Lowers Q1 Loss Y/Y, Focus on Madrigal Merger", "Puma (PBYI) Reports Wider Loss in Q1, Neratinib in Focus", "The Medicines Co. Loss Wider, to Divest Cardiovascular Drugs", "Inovio Incurs Narrower-than-Expected Loss in Q1, Stock Up", "Surging Earnings Estimates Signal Good News for ANI Pharmaceuticals (ANIP)", "Arena's (ARNA) Q1 Loss Narrower but Revenues Fall Short", "GW Pharmaceuticals (GWPH) Q2 Loss Lower than Expected", "Endo (ENDP) Lags Q1 Earnings Estimates, Cuts 2016 Outlook", "Agios (AGIO) Q1 Loss Lower than Expected, Pipeline in Focus", "Conatus (CNAT) Posts In Line Q1 Loss , Focus on Emricasan", "Geron (GERN) Q1 Loss In-Line, Imetelstat Remains in Focus", "Celldex (CLDX) Posts Wider Q1 Loss, Focus on Pipeline", "Horizon (HZNP) Stock Up Despite Earnings & Revenue Miss", "AMAG (AMAG) Q1 Earnings Beat Estimates, Keeps 2016 View", "Zoetis (ZTS) Tops Q1 Earnings & Revenues, Updates Outlook", "Illumina (ILMN) Misses on Q1 Earnings, Lowers '16 Guidance", "VIVUS (VVUS) Q1 Loss Narrower but Qsymia Sales Decline", "Mylan Beats on Q1 Earnings, Revenues Lag, 2016 View Intact", "SurModics (SRDX) Beats Q2 Earnings & Revenues Estimates", "Novo Nordisk (NVO) Beats on Q1 Earnings, Retains Outlook", "Regeneron (REGN) Tops Q1 Earnings, Ups 2016 Eylea View", "Integra (IART) Beats on Q1 Earnings, Grows Organically", "New Strong Buy Stocks for April 26th", "Health Care Sector Update for 04/05/2016: ICPT, ANIP", "Health Care Sector Update for 01/05/2016: ANIP, GALT, IMMU", "Health Care Sector Update for 12/29/2015: USO, UNG, ERB", "3 Great Biotech Stocks You Haven't Heard Of", "ANI Pharmaceuticals (ANIP): An Off-the-Radar Potential Winner", "Cambrex (CBM) Catches Eye: Stock Adds 8.5% in Session", "ANI Pharmaceuticals (ANIP) in Focus: Stock Surges 10.5%", "5 Sell-Ranked Biotechs That Fell More Than 5% Today", "ANI Pharmaceuticals (ANIP) Falls: Stock Goes Down 15.8%", "Company News for September 22, 2015", "ANI Pharmaceuticals Inks Deal with Merck for 2 NDAs", "Should You Get Rid of ANI Pharmaceuticals (ANIP) Now?", "New Strong Sell Stocks for August 6th - Tale of the Tape", "New Strong Sell Stocks for October 13th", "New Strong Sell Stocks for July 2nd - Tale of the Tape", "New Strong Sell Stocks for June 29th - Tale of the Tape", "New Strong Sell Stocks for June 18th - Tale of the Tape", "New Strong Sell Stocks for June 9th - Tale of the Tape", "New Strong Sell Stocks for June 4th - Tale of the Tape", "Undervalued Stocks in Biotech Worth Buying", "New Strong Sell Stocks for May 22nd - Tale of the Tape", "Health Care Sector Update for 07/13/2015: NVLS, CLTX, ANIP", "3 Comeback Stocks to Buy in Healthcare", "10 Most Profitable Companies in Healthcare", "OncoMed Down on Phase Ib Lung Cancer Study Data - Analyst Blog", "Oncolytics' Reolysin Gets One More Orphan Drug Status - Analyst Blog", "TrovaGene's (TROV) PCM Data Impresses, Shares Rally - Analyst Blog", "Receptos Gains on Positive Phase II Data on Ozanimod - Analyst Blog", "Actelion to Boost Progress of Specialty Immunology Pipeline - Analyst Blog", "Why ANI Pharmaceuticals (ANIP) Could Be Positioned for a Slump - Tale of the Tape", "Glaxo Downgraded to Strong Sell, Delete from Your Portfolio - Analyst Blog", "GW Pharmaceuticals Up to Strong Buy on Strong Pipeline - Analyst Blog", "ARCA biopharma Gains on Fast Track Status for Gencaro - Analyst Blog", "Aeterna Zentaris to Advance Hormone Drug to Phase III Study - Analyst Blog", "Adamas Pharma's Lead Candidate Gets Orphan Status in U.S. - Analyst Blog", "Horizon Pharma's Actimmune Gets Fast Track Status - Analyst Blog", "Health Care Sector Update for 04/10/2015: ARNA, VRTX, ANIP", "The Medicines Co.'s Kengreal Backed for FDA Approval - Analyst Blog", "Clovis Oncology's Rucaparib Gets Breakthrough Status - Analyst Blog", "SAGE Therapeutics' Lead Candidate to Enter Phase III Study - Analyst Blog", "Can Qiagen Continue to Grow in Molecular Diagnostics Space? - Analyst Blog", "Heat Biologics Posts Wider Loss Y/Y, Focus on Pipeline - Analyst Blog", "Novo Nordisk to Submit Interim DEVOTE Data to the FDA - Analyst Blog", "Novo Nordisk's Onset 1 & Onset 2 Meet Primary Objectives - Analyst Blog", "Regeneron's Eylea Gets FDA Approval for Label Expansion - Analyst Blog", "Novo Nordisk's Tresiba & Ryzodeg NDAs under FDA Review - Analyst Blog", "Isis Pharmaceuticals Reports Phase I Data on Lipid Candidate - Analyst Blog", "Myriad Poised on Portfolio Strength Despite Y/Y Downfall in Q2 - Analyst Blog", "Eli Lilly Partners with Innovent to Develop Oncology Drugs - Analyst Blog", "Pfizer Reveals Detailed Xeljanz Data from Psoriasis Study - Analyst Blog", "Prothena's PRX002 Positive in Parkinson's Disease Study - Analyst Blog", "Amicus to Seek for Migalastat's Approval in the U.S., EU - Analyst Blog", "Eli Lilly Collaborates with Korean Hanmi Pharmaceutical - Analyst Blog", "Lpath (LPTN) Crumbles on Failure of Kidney Cancer Drug Trial - Analyst Blog", "Genomic Health Prostrate Cancer Test Grows but Hits Margins - Analyst Blog", "Kite Pharma (KITE) Acquires T-Cell Factory, Focus on Europe - Analyst Blog", "Epizyme (EPZM) Crumbles: Stock Falls by 9.6% - Tale of the Tape", "Actelion's Uptravi Shows Long-term Benefit in GRIPHON - Analyst Blog", "Epizyme's Loss Narrower than Expected, Focus on Pipeline - Analyst Blog", "Synta's Q4 Loss Narrows Y/Y, Focus on Lung Cancer Drug - Analyst Blog", "TrovaGene (TROV) Posts Wider Q4 Loss on Higher Expenses - Analyst Blog", "Lexicon-Ipsen Agreement Expanded to Include Canada - Analyst Blog", "Genomic Health Prostrate Cancer Test Grows but Hits Margins - Analyst Blog", "Regado Biosciences (RGDO) Jumps: Stock Surges 20.3% - Tale of the Tape", "Myriad Genetics Unveils Simoa-based Immunoassay Services - Analyst Blog", "Bristol-Myers Oncology Drug Opdivo Label Expanded in U.S. - Analyst Blog", "Fibrocell Science (FCSC) in Focus: Stock Surges 11% - Tale of the Tape", "Is Illumina (ILMN) Worth Adding to Your Portfolio Now? - Analyst Blog", "Amgen-Celimmune Tie Up for Autoimmune Disorder Drug - Analyst Blog", "Is Illumina (ILMN) Worth Adding to Your Portfolio Now? - Analyst Blog", "Keryx Biopharmaceuticals' Q4 Loss Wider than Expected - Analyst Blog", "Roche's Avastin Gets Positive Opinion for Cervical Cancer - Analyst Blog", "Gilead's (GILD) HIV Drug Positive in 2 Phase III Studies - Analyst Blog", "Alexion's Soliris' Label May be Updated upon EC Approval - Analyst Blog", "Amgen's Kyprolis Under EU Review - Analyst Blog", "Aegerion's Q4 Loss Narrows Y/Y, Ups Juxtapid Sales View - Analyst Blog", "Merge Healthcare (MRGE) Q4 Earnings Up Y/Y; Revenues Miss - Analyst Blog", "Bristol-Myers Files for New Indications for Yervoy, Opdivo - Analyst Blog", "Illumina Expands NGS Portfolio with NeoPrep Library System - Analyst Blog", "Zacks Rank #1 Additions for Friday - Tale of the Tape", "SPDR S&P Pharmaceuticals ETF -- Insider Buying Index Registering 10.1%", "AMAG, Takeda Mutually End Agreement for Feraheme - Analyst Blog", "BioMarin's Vimizim OK'd in Japan for Morquio A Syndrome - Analyst Blog", "Actelion Submits New Drug Application for Uptravi in the U.S. - Analyst Blog", "Stryker & Osiris Team Up to Market Viable Bone Matrix - Analyst Blog", "Integra Lifesciences Tops Q4 Earnings, Revenues; Up Y/Y - Analyst Blog", "Illumina Expands NGS Portfolio with NeoPrep Library System - Analyst Blog", "Zacks Rank #1 Additions for Friday - Tale of the Tape", "Bruker Unveils bioAFM System for High Resolution Imaging - Analyst Blog", "OvaScience Slumps: OVAS Tanks 12.3% in Session - Tale of the Tape", "BioDelivery Sciences (BDSI) in Focus: Stock Tanks 11% - Tale of the Tape", "Alkermes Starts Phase I Study on Schizophrenia Candidate - Analyst Blog", "Acorda's Ampyra in Phase III for Post-Stroke Walking Deficit - Analyst Blog", "Will myRisk Cancer Test Work Wonders for Myriad Genetics? - Analyst Blog", "One Stock Chart Trick You Should All Know - Investment Ideas", "Strength Seen in GTX Inc (GTXI): Stock Rises 10.6% - Tale of the Tape", "Alder Biopharmaceuticals Slumps: ALDR Falls 5.5% in Session - Tale of the Tape", "Alexion's Soliris Receives Orphan Drug Status in Japan - Analyst Blog", "Sangamo Biosciences (SGMO) Jumps: Stock Rises 7.2% - Tale of the Tape", "Alder Biopharmaceuticals Inc. (ALDR) in Focus: Stock Soars 31.9% - Tale of the Tape", "Celladon Corporation (CLDN) Falls: Stock Goes Down 8.6% - Tale of the Tape", "Genomic Health's Breast Cancer Test Yields Positive Results - Analyst Blog", "Genomic Health's Liquid Biopsy Tests Positive in Twin Studies - Analyst Blog", "Kite Pharma (KITE) Shows Strength: Stock Moves Up 16.4% - Tale of the Tape", "Avalanche Biotechnologies (AAVL) Jumps: Stock Adds 6.1% in Session - Tale of the Tape", "Celladon Corp. (CLDN) Jumps: Stock Adds 14.7% in Session - Tale of the Tape", "Myriad Genetics Unveils Positive Cancer Study Results - Analyst Blog", "Rexahn Pharmaceuticals, Inc. (RNN) Rises: Stock Up 8.6% - Tale of the Tape", "Acceleron Pharma, Inc. (XLRN) in Focus: Stock Soars 13.6% - Tale of the Tape", "Ophthotech Corporation (OPHT) Jumps: Stock Gains 5% - Tale of the Tape", "Genomic Health's Liquid Biopsy Tests Positive in Twin Studies - Analyst Blog", "Kite Pharma (KITE) Shows Strength: Stock Moves Up 16.4% - Tale of the Tape", "Array BioPharma, Inc. (ARRY) in Focus: Stock Soars 14.3% - Tale of the Tape", "Is ANI Pharmaceuticals (ANIP) Stock a Solid Choice Right Now? - Tale of the Tape", "Walgreens (WAG) Up on 4.9% Y/Y Rise in November Sales - Analyst Blog", "Celldex's Glembatumumab Vedotin in Phase II for Melanoma - Analyst Blog", "Cara Therapeutics (CARA) in Focus: Stock Rises 6.1% - Tale of the Tape", "Sequenom Inc. (SQNM) in Focus: Stock Surges 23.6% - Tale of the Tape", "ADMA Biologics' RI-002 Positive in Phase III Study - Analyst Blog", "Health Care Sector Update for 12/04/2014: ANIP,KIN,APPY", "Genomic Health's Oncotype DX: Cancer Testing Made Easier - Analyst Blog", "Biogen Idec (BIIB) Shows Strength: Stock Moves 6.4% Up - Tale of the Tape", "Merge Healthcare, NextGen to Expand Interoperability Solution - Analyst Blog", "Myriad Genetics' Prolaris: A Pocket-Friendly Cancer Test - Analyst Blog", "Merge Healthcare (MRGE) Worth Watching: Stock Gains 6.5% - Tale of the Tape", "Coronado Biosciences, Inc. (CNDO) in Focus: Stock Soars 17.6% - Tale of the Tape", "Merge Healthcare, Primordial to Improve Radiology Solutions - Analyst Blog", "What Makes BioDelivery Sciences (BDSI) a Strong Sell? - Tale of the Tape", "Isis Pharmaceuticals Earns Milestone on Study Initiation - Analyst Blog", "Five Prime Therapeutics, Inc. (FPRX) in Focus: Stock Soars 31.4% - Tale of the Tape", "Coronado Biosciences (CNDO) Jumps: Stock Rises 8.5% - Tale of the Tape", "EPIRUS Biopharmaceuticals (EPRS) Jumps: Stock Up 15.9% - Tale of the Tape", "uniQure N.V. (QURE) in Focus: Stock Soars 17.6% - Tale of the Tape", "Novavax Gains on Fast Track Designation for RSV F Vaccine - Analyst Blog", "TrovaGene Cancer Technology Detects KRAS Mutation - Analyst Blog", "Myriad Genetics, Tesaro Tie Up for myChoice Cancer Test - Analyst Blog", "Myriad's Vectra DA: A Better Indicator for Rheumatoid Arthritis - Analyst Blog", "Amarin Corporation plc (AMRN) in Focus: Stock Soars 23.4% - Tale of the Tape", "Omnicell Offers Advanced OT Automation at Hospital in Riyadh - Analyst Blog", "Illumina, bioMerieux to Co-develop NGS Epidemiology Solution - Analyst Blog", "Compugen (CGEN) Worth Watching: Stock Adds 6% in Session - Tale of the Tape", "Celldex Therapeutics, Inc. (CLDX) in Focus: Stock Soars 28.9% - Tale of the Tape", "Kite Pharma Gains on Positive Opinion for KTE-C19 - Analyst Blog", "Kite Pharma's Q3 Loss Narrows Y/Y, Focus on Pipeline - Analyst Blog", "Puma Biotechnology Slumps: PBYI Tumbles 9.7% in Session - Tale of the Tape", "Integra (IART) Strengthens Spinal Implant with Twin Launches - Analyst Blog", "Affymetrix (AFFX) Now a Strong Buy, Raised Guidance Positive - Analyst Blog", "Intercept Pharmaceuticals Slumps: ICPT Falls 5.9% in Session - Tale of the Tape", "Amicus Therapeutics, Inc. (FOLD) in Focus: Stock Soars 17.8% - Tale of the Tape", "ANI Pharma (ANIP) & Sucampo Pharma (SCMP): Top Momentum Stocks to Add to Your Portfolio - Video Blog", "Why ANI Pharmaceuticals (ANIP) Could Be Positioned for a Surge? - Tale of the Tape", "Zacks Rank #1 Additions for Thursday - Tale of the Tape", "Celldex Falls with Pipeline Update Overshadowing Q3 Results - Analyst Blog", "Insider Bets Paying Off At ANIP As New 52-Week High Reached", "3 Money-Making Biotech Stocks That Could Go Higher", "Zacks Rank #5 Additions for Monday - Tale of the Tape", "Can the Rally in ANI Pharmaceuticals (ANIP) Shares Continue? - Tale of the Tape", "ANI Pharmaceuticals (ANIP) in Focus: Stock Surges 11% - Tale of the Tape", "Sector Update: Health Care", "Sector Update: Health Care Stocks Underwater as a Group; ANI Pharma Jumps after Narrowing Q2 Net Loss, Growing Revenue", "Walgreens Sees Robust Growth in June Sales - Analyst Blog", "UCB, Dermira Sign Cimzia Dermatology Deal - Analyst Blog", "Jazz Pharmaceuticals to Buy Rights to Defibrotide, Shares Up - Analyst Blog", "Sanofi and CureVac Ink Vaccine Deal - Analyst Blog", "Zacks Rank #5 Additions for Tuesday - Tale of the Tape", "Edwards Lifesciences Monitor Gets FDA Nod - Analyst Blog", "Geron Corp. (GERN) Jumps: Stock Moves 8.1% Higher - Tale of the Tape", "Dicerna Pharmaceuticals (DRNA) Soars: Stock Rises 19.8% - Tale of the Tape", "AVEO Pharmaceuticals (AVEO) Jumps: Stock Rises 6.4% - Tale of the Tape", "Curis (CRIS) Soars: Stock Adds 11.4% in Session - Tale of the Tape", "Illumina Expands in Europe on 3 NIPT Deals - Analyst Blog", "UCB's Vimpat Positive for Partial-Onset Seizures - Analyst Blog", "Strength Seen in Amicus Therapeutics, Inc. (FOLD) as Stock Rallies 19.46% - Tale of the Tape", "Dyax Corp. (DYAX) Soars: Stock Rises 12.5% - Tale of the Tape", "Discovery Laboratories Inc. (DSCO) in Focus: Stock Rises 7.83% - Tale of the Tape", "Integra Lifesciences Down to Sell - Analyst Blog", "Pacira's Exparel Positive in Phase IV Studies - Analyst Blog", "Bruker's MALDI Biotyper Approved for Biochemical Testing in China - Analyst Blog", "Prothena Corporation (PRTA) Falls: Stock Goes Down 5.3% - Tale of the Tape", "Glaxo's Promacta in Phase III for MDS - Analyst Blog", "BIND Therapeutics (BIND) Soars: Stock Adds 9.1% in Session - Tale of the Tape", "Nanosphere (NSPH) Jumps: Stock Rises 14.6% - Tale of the Tape", "Alkermes plc (ALKS) Jumps: Stock Rises 5.7% - Tale of the Tape", "Strength Seen in Cara Therapeutics Inc. (CARA) as Stock Rallies 19.60% - Tale of the Tape", "Ultragenyx Pharmaceutical (RARE) Jumps: Stock Up 6.5% - Tale of the Tape", "Insmed Incorporated (INSM) Catches Eye: Stock Surges 42.6% - Tale of the Tape", "Protalix (PLX) in Focus: Stock Adds 6.5% in Session - Tale of the Tape", "Acorda Therapeutics (ACOR) in Focus: Stock Moves 7.8% Higher - Tale of the Tape", "Strength Seen in Vertex Pharmaceuticals Incorporated (VRTX) as Stock Shoots 40.41% - Tale of the Tape", "Intra-Cellular Therapies, Inc. (ITCI) in Focus: Stock Rises 8.74% - Tale of the Tape", "AVEO Pharmaceuticals (AVEO) Catches Eye: Stock Up 11.4% - Tale of the Tape", "Orexigen (OREX) in Focus: Stock Moves 7.5% Higher - Tale of the Tape", "Sequenom Inc. (SQNM) Soars: Stock Rises 9.2% - Tale of the Tape", "Achillion Pharmaceuticals (ACHN) Jumps: Stock Up 20.9% - Tale of the Tape", "Strength Seen in bluebird bio, Inc. (BLUE) as Stock Shoots up 32.08% - Tale of the Tape", "What Falling Estimates & Price Mean for Rexahn Pharmaceuticals (RNN) - Tale of the Tape", "Applied Genetic Technologies (AGTC) Jumps: Stock Up 6.1% - Tale of the Tape", "Integra LifeSciences, Premier Ink 3-Year Purchase Deal - Analyst Blog", "Will Forest Labs Retain Namenda Market Share? - Analyst Blog", "BIND Therapeutics (BIND) Soars: Stock Up 6.8% - Tale of the Tape", "Sunesis Pharmaceuticals (SNSS) Soars: Stock Adds 8% in Session - Tale of the Tape", "Progenics Pharmaceuticals, Inc. (PGNX) in Focus: Stock Rises 9.23% - Tale of the Tape", "Avanir Gains - AVP-825 Hits Phase III Primary Endpoint - Analyst Blog", "Auxilium Pharma Launches Authorized Generic Testim - Analyst Blog", "Actelion's Selexipag Meets Primary Endpoint - Analyst Blog", "Vital Therapies (VTL) Catches Eye: Stock Surges 20.7% - Tale of the Tape", "Orexigen Therapeutics (OREX) in Focus: Stock Tumbles 14.7% - Tale of the Tape", "BioDelivery Sciences International (BDSI) Jumps: Stock Up 14.1% - Tale of the Tape", "Achillion Pharmaceuticals (ACHN) in Focus: Stock Falls 6.4% - Tale of the Tape", "Ocera Therapeutics (OCRX) Soars: Stock Adds 11.8% in Session - Tale of the Tape", "Genomic Health's Oncotype DX Redefines Breast Cancer Therapy - Analyst Blog", "Merck KGaA & MorphoSys Sign Deal, Immuno-Oncology in Focus - Analyst Blog", "Geron Corp. (GERN) Soars: Stock Up 10.6% - Tale of the Tape", "Merck KGaA/Auxogyn's Eeva System Gets FDA Clearance - Analyst Blog", "Isis Pharma Earns Milestone Payment on Study Initiation - Analyst Blog", "Strength Seen in Inovio (INO): Stock Rises 9.4% - Tale of the Tape", "Achillion Pharmaceuticals (ACHN) in Focus: Stock Rises 47.6% - Tale of the Tape", "Why Puma Biotechnology (PBYI) Could Be Positioned for a Slump - Tale of the Tape", "Idenix Pharmaceuticals (IDIX) Soars: Stock Rises 229.1% - Tale of the Tape", "AVEO Pharmaceuticals, Inc. (AVEO) in Focus: Stock Rises 7.8% - Tale of the Tape", "Oragenics (OGEN) in Focus: Stock Adds 6% in Session - Tale of the Tape", "Fibrocell Science (FCSC) in Focus: Stock Rises 14.4% - Tale of the Tape", "Novavax (NVAX) Crumbles: Stock Tumbles by 7.7% - Tale of the Tape", "BioDelivery Sciences' Bunavail Gets FDA Nod - Analyst Blog", "Celldex Therapeutics (CLDX) Soars: Stock Adds 12.6% in Session - Tale of the Tape", "Clovis Oncology (CLVS) Jumps: Stock Rises 6.2% - Tale of the Tape", "Affymetrix, BioDiscovery Launch Cancer Research Software - Analyst Blog", "MannKind Corp. (MNKD) Soars: Stock Adds 10.8% in Session - Tale of the Tape", "Integra Lifesciences Down to Sell on Poor Q1 Segment Show - Analyst Blog", "Acadia Healthcare Company (ACHC) CQH Soars: Stock Adds 14.1% in Session - Tale of the Tape", "Applied Genetic (AGTC) Soars: Stock Up 44.1% - Tale of the Tape", "Eli Lilly's Cyramza 'REVELs' in Phase III - Analyst Blog", "Myriad Genetics Posts Key myPath Melanoma Data - Analyst Blog", "Allergan Inc. (AGN) in Focus: Stock Rises 5.65% - Tale of the Tape", "Sanofi's Lemtrada Accepted for FDA Review - Analyst Blog", "Amicus Therapeutics (FOLD) Soars: Stock Up 10% - Tale of the Tape", "Halozyme Study Clinical Hold Lifted by FDA - Analyst Blog", "Genomic Health Posts Fresh Oncotype DX Data - Analyst Blog", "Xenoport, Inc. (XNPT) Soars: Stock Up 5.9% - Tale of the Tape", "GTX Inc. (GTXI) Soars: Stock Up 9.7% - Tale of the Tape", "Verastem (VSTM) in Focus: Stock Adds 14% in Session - Tale of the Tape", "Isis Pharmaceuticals, Inc. (ISIS) in Focus: Stock Rises 9.21% - Tale of the Tape", "Strength Seen in PTC Therapeutics, Inc. (PTCT) as Stock Shoots up 30.74% - Tale of the Tape", "Medtronic Unveils New CoreValve Data - Analyst Blog", "ArQule Inc. (ARQL) in Focus: Stock Rises 8.21% - Tale of the Tape", "Why ANI Pharmaceuticals (ANIP) Could Shock the Market Soon - Tale of the Tape", "Auspex Pharmaceuticals (ASPX) Jumps: Stock Rises 9.5% - Tale of the Tape", "Myriad Genetics Unveils Positive Prolaris Data - Analyst Blog", "Genomic Health: Study Boosts Oncotype DX Again - Analyst Blog", "CareFusion Hits New 52-Week High - Analyst Blog", "Genomic Health Presents New Oncotype DX Data - Analyst Blog", "XenoPort - Reckitt Benckiser Pharma Collaborate - Analyst Blog", "Insmed (INSM) in Focus: Stock Moves 6.7% Higher - Tale of the Tape", "Progenics' Q1 Loss Narrows - Analyst Blog", "Myriad Genetics Arm Offers New Vectra DA Data - Analyst Blog", "AdCare Health Systems (ADK) in Focus: Stock Moves 5.1% Higher - Tale of the Tape", "Halozyme Therapeutics, Inc. (HALO) in Focus: Stock Up 6.9% - Tale of the Tape", "Pipeline Update from BioDelivery Sciences - Analyst Blog", "XenoPort's Q1 Loss Narrows - Analyst Blog", "Halozyme's Q1 Loss Widens - Analyst Blog", "Clovis Oncology, Inc. (CLVS) in Focus: Stock Surges 16 % - Tale of the Tape", "RadNet (RDNT) Surges: Stock Moves 21.8% Higher - Tale of the Tape", "Illumina Upgraded to Strong Buy - Analyst Blog", "XOMA Posts Wider Q1 Loss - Analyst Blog", "Q1 Loss Wider than Expected at Genomic Health - Analyst Blog", "Zacks Rank #1 Additions for Thursday - Tale of the Tape", "Narrower-than-Expected Loss at Cepheid, View Tweaked - Analyst Blog", "Transition Therapeutics (TTHI) Jumps: Stock Up 11.5% - Tale of the Tape", "RadNet Touches New 52-Week High - Analyst Blog", "Kythera Biopharmaceuticals, Inc. (KYTH) in Focus: Stock Surges 9.9 % - Tale of the Tape", "Rite Aid (RAD) Jumps: Stock Up 8.4% - Tale of the Tape", "Gilead Sciences (GILD) Falls: Stock Goes Down 7.3% - Tale of the Tape", "Celladon (CLDN) Jumps: Stock Up 11.5% - Tale of the Tape", "Baxano Surgical, Inc. (BAXS) in Focus: Stock up 10.7% - Tale of the Tape", "Qiagen Expands Personalized Healthcare Pipeline - Analyst Blog", "RadNet Touches New 52-Week High - Analyst Blog", "ImmunoGen, Inc. (IMGN) in Focus: Stock Rallies 11% - Tale of the Tape", "Kythera Biopharmaceuticals, Inc. (KYTH) in Focus: Stock Surges 9.9 % - Tale of the Tape", "Questcor Pharmaceuticals (QCOR) Shows Strength: Stock Surges 18.7% in Session - Tale of the Tape", "Response Genetics (RGDX) in Focus: Stock Up 18.3% - Tale of the Tape", "Acceleron Pharma (XLRN) Jumps: Stock Up 13.2% - Tale of the Tape", "Exact Sciences (EXAS) Jumps: Stock Adds 10.2% in Session - Tale of the Tape", "Insmed Incorporated saw its shares rise more than 7% in the session. - Tale of the Tape", "Integra LifeSciences Introduces Wound Matrix - Analyst Blog", "Idenix Pharmaceuticals (IDIX) Jumps: Stock Up 12.4% - Tale of the Tape", "Puma Biotechnology (PBYI) in Focus: Stock Tumbles 18.3% - Tale of the Tape", "Questcor Pharmaceuticals (QCOR) Shows Strength: Stock Surges 18.7% in Session - Tale of the Tape", "Biogen's Alprolix Approved in Canada - Analyst Blog", "Strength Seen in ZIOPHARM Oncology (ZIOP): Stock Up 11.8% - Tale of the Tape", "Oncolytics Biotech (ONCY) Jumps: Stock Rises 5% - Tale of the Tape", "Qiagen's QuantiFERON-TB Test Now in China - Analyst Blog", "Prothena (PRTA) Jumps: Stock Rises 27.5% - Tale of the Tape", "CVS Caremark Receives FEP contract - Analyst Blog", "China Cord Blood Corporation (CO) Soars: Stock Up 5.7% - Tale of the Tape", "Horizon Pharma (HZNP) Jumps: Stock Rises 5.6% - Tale of the Tape", "Five Prime Therapeutics (FPRX) Surges: Stock Moves 22.6% Higher - Tale of the Tape", "Insmed (INSM) Looks Good: Stock Adds 5.9% in Session - Tale of the Tape", "First Laminoplasty Implant at Integra - Analyst Blog", "Can The Uptrend Continue for ANI Pharmaceuticals (ANIP)? - Tale of the Tape", "Surging Earnings Estimates Signal Good News for ANI Pharmaceuticals (ANIP) - Tale of the Tape", "Why ANI Pharmaceuticals (ANIP) Has a Bright Short-Term Future? - Tale of the Tape", "Company news for December 30, 2013 - Corporate Summary", "Post-TEVA Deal, ANIP Shares Rise - Analyst Blog", "Tuesday Sector Leaders: Biotechnology, Drugs"], "Elapsed Time": ["JUN 3, 2020", "MAY 8, 2020", "MAY 7, 2020", "MAY 7, 2020", "MAY 7, 2020", "APR 29, 2020", "APR 17, 2020", "APR 15, 2020", "JUN 3, 2020", "APR 2, 2020", "FEB 27, 2020", "FEB 27, 2020", "FEB 27, 2020", "FEB 27, 2020", "FEB 12, 2020", "FEB 10, 2020", "APR 14, 2020", "JAN 9, 2020", "DEC 3, 2019", "NOV 6, 2019", "OCT 3, 2019", "AUG 7, 2019", "AUG 7, 2019", "AUG 7, 2019", "JAN 16, 2020", "MAY 9, 2019", "MAY 9, 2019", "MAY 6, 2019", "APR 18, 2019", "APR 17, 2019", "APR 12, 2019", "APR 5, 2019", "MAY 10, 2019", "JAN 1, 2019", "NOV 30, 2018", "NOV 20, 2018", "NOV 6, 2018", "JUL 6, 2018", "JUL 6, 2018", "JUL 5, 2018", "FEB 28, 2019", "JUL 4, 2018", "JUL 3, 2018", "JUL 3, 2018", "JUN 29, 2018", "JUN 29, 2018", "JUN 28, 2018", "JUN 28, 2018", "JUL 5, 2018", "JUN 26, 2018", "JUN 26, 2018", "JUN 26, 2018", "JUN 26, 2018", "JUN 25, 2018", "JUN 21, 2018", "JUN 27, 2018", "JUN 20, 2018", "JUN 20, 2018", "JUN 20, 2018", "JUN 19, 2018", "JUN 19, 2018", "JUN 14, 2018", "JUN 14, 2018", "JUN 20, 2018", "JUN 20, 2018", "MAY 21, 2018", "MAR 14, 2018", "FEB 2, 2018", "JAN 26, 2018", "JAN 18, 2018", "MAY 29, 2018", "MAY 25, 2018", "MAY 23, 2018", "JAN 5, 2018", "JAN 4, 2018", "JAN 4, 2018", "JAN 3, 2018", "JAN 3, 2018", "JAN 12, 2018", "JAN 11, 2018", "NOV 29, 2017", "NOV 27, 2017", "NOV 27, 2017", "NOV 16, 2017", "NOV 13, 2017", "DEC 19, 2017", "NOV 7, 2017", "OCT 24, 2017", "OCT 16, 2017", "OCT 11, 2017", "AUG 21, 2017", "JUN 12, 2017", "MAY 11, 2017", "NOV 8, 2017", "MAR 1, 2017", "JAN 23, 2017", "JAN 7, 2017", "NOV 3, 2016", "OCT 5, 2016", "OCT 5, 2016", "OCT 4, 2016", "MAR 13, 2017", "OCT 3, 2016", "OCT 3, 2016", "OCT 3, 2016", "SEP 28, 2016", "SEP 28, 2016", "SEP 28, 2016", "SEP 28, 2016", "OCT 4, 2016", "SEP 27, 2016", "SEP 27, 2016", "SEP 26, 2016", "SEP 26, 2016", "SEP 26, 2016", "SEP 26, 2016", "SEP 23, 2016", "SEP 28, 2016", "SEP 22, 2016", "SEP 22, 2016", "SEP 22, 2016", "SEP 21, 2016", "SEP 21, 2016", "SEP 21, 2016", "SEP 21, 2016", "SEP 23, 2016", "SEP 21, 2016", "SEP 21, 2016", "SEP 20, 2016", "SEP 20, 2016", "SEP 20, 2016", "SEP 20, 2016", "SEP 20, 2016", "SEP 21, 2016", "SEP 20, 2016", "SEP 20, 2016", "SEP 19, 2016", "SEP 19, 2016", "SEP 19, 2016", "SEP 19, 2016", "SEP 19, 2016", "SEP 20, 2016", "SEP 16, 2016", "SEP 16, 2016", "SEP 16, 2016", "SEP 16, 2016", "SEP 16, 2016", "SEP 15, 2016", "SEP 15, 2016", "SEP 19, 2016", "SEP 15, 2016", "SEP 15, 2016", "SEP 15, 2016", "SEP 15, 2016", "SEP 15, 2016", "SEP 15, 2016", "SEP 15, 2016", "SEP 15, 2016", "SEP 14, 2016", "SEP 14, 2016", "SEP 14, 2016", "SEP 14, 2016", "SEP 14, 2016", "SEP 13, 2016", "SEP 13, 2016", "SEP 15, 2016", "SEP 13, 2016", "SEP 13, 2016", "SEP 13, 2016", "SEP 13, 2016", "SEP 13, 2016", "SEP 12, 2016", "SEP 12, 2016", "SEP 13, 2016", "SEP 9, 2016", "SEP 8, 2016", "SEP 8, 2016", "SEP 8, 2016", "SEP 7, 2016", "SEP 7, 2016", "SEP 7, 2016", "SEP 12, 2016", "SEP 6, 2016", "SEP 6, 2016", "SEP 6, 2016", "SEP 6, 2016", "SEP 6, 2016", "SEP 6, 2016", "SEP 6, 2016", "SEP 6, 2016", "SEP 5, 2016", "SEP 5, 2016", "SEP 2, 2016", "SEP 2, 2016", "SEP 2, 2016", "SEP 1, 2016", "SEP 1, 2016", "SEP 5, 2016", "SEP 1, 2016", "AUG 31, 2016", "AUG 31, 2016", "AUG 31, 2016", "AUG 31, 2016", "AUG 31, 2016", "AUG 31, 2016", "SEP 1, 2016", "AUG 30, 2016", "AUG 30, 2016", "AUG 30, 2016", "AUG 30, 2016", "AUG 30, 2016", "AUG 29, 2016", "AUG 29, 2016", "AUG 30, 2016", "AUG 26, 2016", "AUG 26, 2016", "AUG 25, 2016", "AUG 25, 2016", "AUG 25, 2016", "AUG 24, 2016", "AUG 24, 2016", "AUG 29, 2016", "AUG 26, 2016", "AUG 26, 2016", "AUG 23, 2016", "AUG 23, 2016", "AUG 23, 2016", "AUG 23, 2016", "AUG 23, 2016", "AUG 24, 2016", "AUG 22, 2016", "AUG 22, 2016", "AUG 22, 2016", "AUG 22, 2016", "AUG 19, 2016", "AUG 19, 2016", "AUG 19, 2016", "AUG 22, 2016", "AUG 18, 2016", "AUG 18, 2016", "AUG 18, 2016", "AUG 18, 2016", "AUG 17, 2016", "AUG 17, 2016", "AUG 17, 2016", "AUG 18, 2016", "AUG 17, 2016", "AUG 17, 2016", "AUG 17, 2016", "AUG 17, 2016", "AUG 16, 2016", "AUG 16, 2016", "AUG 16, 2016", "AUG 17, 2016", "AUG 16, 2016", "AUG 16, 2016", "AUG 15, 2016", "AUG 12, 2016", "AUG 12, 2016", "AUG 11, 2016", "AUG 10, 2016", "AUG 16, 2016", "AUG 10, 2016", "AUG 10, 2016", "AUG 10, 2016", "AUG 10, 2016", "AUG 10, 2016", "AUG 9, 2016", "AUG 9, 2016", "AUG 10, 2016", "AUG 9, 2016", "AUG 9, 2016", "AUG 9, 2016", "AUG 5, 2016", "AUG 5, 2016", "AUG 4, 2016", "AUG 4, 2016", "AUG 9, 2016", "AUG 4, 2016", "AUG 3, 2016", "AUG 3, 2016", "AUG 2, 2016", "AUG 2, 2016", "AUG 2, 2016", "AUG 2, 2016", "AUG 4, 2016", "AUG 2, 2016", "AUG 1, 2016", "AUG 1, 2016", "AUG 1, 2016", "AUG 1, 2016", "AUG 1, 2016", "AUG 1, 2016", "AUG 2, 2016", "JUL 29, 2016", "JUL 29, 2016", "JUL 29, 2016", "JUL 29, 2016", "JUL 29, 2016", "JUL 29, 2016", "JUL 29, 2016", "AUG 1, 2016", "JUL 29, 2016", "JUL 29, 2016", "JUL 28, 2016", "JUL 28, 2016", "JUL 28, 2016", "JUL 28, 2016", "JUL 28, 2016", "JUL 29, 2016", "JUL 28, 2016", "JUL 28, 2016", "JUL 27, 2016", "JUL 27, 2016", "JUL 26, 2016", "JUL 22, 2016", "JUL 22, 2016", "JUL 28, 2016", "JUL 21, 2016", "JUL 6, 2016", "JUL 5, 2016", "JUL 5, 2016", "JUL 4, 2016", "JUL 4, 2016", "JUL 1, 2016", "JUL 21, 2016", "JUL 21, 2016", "JUL 6, 2016", "JUL 5, 2016", "JUN 29, 2016", "JUN 29, 2016", "JUN 29, 2016", "JUN 28, 2016", "JUL 1, 2016", "JUN 28, 2016", "JUN 27, 2016", "JUN 27, 2016", "JUN 27, 2016", "JUN 24, 2016", "JUN 24, 2016", "JUN 24, 2016", "JUN 28, 2016", "JUN 24, 2016", "JUN 24, 2016", "JUN 24, 2016", "JUN 23, 2016", "JUN 23, 2016", "JUN 23, 2016", "JUN 23, 2016", "JUN 24, 2016", "JUN 23, 2016", "JUN 22, 2016", "JUN 22, 2016", "JUN 22, 2016", "JUN 21, 2016", "JUN 21, 2016", "JUN 21, 2016", "JUN 23, 2016", "JUN 21, 2016", "JUN 21, 2016", "JUN 21, 2016", "JUN 20, 2016", "JUN 20, 2016", "JUN 17, 2016", "JUN 17, 2016", "JUN 21, 2016", "JUN 21, 2016", "JUN 16, 2016", "JUN 15, 2016", "JUN 14, 2016", "JUN 14, 2016", "JUN 13, 2016", "JUN 13, 2016", "JUN 16, 2016", "JUN 8, 2016", "JUN 8, 2016", "JUN 7, 2016", "JUN 7, 2016", "JUN 7, 2016", "JUN 6, 2016", "JUN 6, 2016", "JUN 10, 2016", "JUN 6, 2016", "JUN 6, 2016", "JUN 6, 2016", "JUN 3, 2016", "JUN 3, 2016", "JUN 2, 2016", "JUN 2, 2016", "JUN 6, 2016", "JUN 1, 2016", "JUN 1, 2016", "JUN 1, 2016", "JUN 1, 2016", "JUN 1, 2016", "JUN 1, 2016", "JUN 1, 2016", "JUN 2, 2016", "MAY 31, 2016", "MAY 30, 2016", "MAY 27, 2016", "MAY 27, 2016", "MAY 27, 2016", "MAY 26, 2016", "MAY 26, 2016", "MAY 31, 2016", "MAY 25, 2016", "MAY 25, 2016", "MAY 25, 2016", "MAY 25, 2016", "MAY 25, 2016", "MAY 25, 2016", "MAY 26, 2016", "MAY 24, 2016", "MAY 24, 2016", "MAY 24, 2016", "MAY 24, 2016", "MAY 23, 2016", "MAY 23, 2016", "MAY 23, 2016", "MAY 25, 2016", "MAY 20, 2016", "MAY 19, 2016", "MAY 19, 2016", "MAY 19, 2016", "MAY 18, 2016", "MAY 18, 2016", "MAY 17, 2016", "MAY 20, 2016", "MAY 16, 2016", "MAY 16, 2016", "MAY 13, 2016", "MAY 13, 2016", "MAY 13, 2016", "MAY 13, 2016", "MAY 12, 2016", "MAY 17, 2016", "MAY 12, 2016", "MAY 11, 2016", "MAY 11, 2016", "MAY 11, 2016", "MAY 11, 2016", "MAY 10, 2016", "MAY 10, 2016", "MAY 12, 2016", "MAY 10, 2016", "MAY 6, 2016", "MAY 6, 2016", "MAY 6, 2016", "MAY 6, 2016", "MAY 6, 2016", "MAY 6, 2016", "MAY 10, 2016", "MAY 4, 2016", "MAY 4, 2016", "MAY 4, 2016", "MAY 4, 2016", "MAY 3, 2016", "MAY 3, 2016", "MAY 2, 2016", "MAY 5, 2016", "APR 28, 2016", "APR 26, 2016", "APR 5, 2016", "JAN 5, 2016", "DEC 29, 2015", "DEC 19, 2015", "NOV 30, 2015", "MAY 2, 2016", "OCT 6, 2015", "SEP 25, 2015", "SEP 23, 2015", "SEP 22, 2015", "SEP 22, 2015", "AUG 12, 2015", "AUG 7, 2015", "OCT 13, 2015", "JUL 2, 2015", "JUN 29, 2015", "JUN 18, 2015", "JUN 9, 2015", "JUN 4, 2015", "MAY 28, 2015", "MAY 22, 2015", "JUL 13, 2015", "MAY 12, 2015", "MAY 7, 2015", "APR 20, 2015", "APR 20, 2015", "APR 20, 2015", "APR 17, 2015", "APR 16, 2015", "MAY 13, 2015", "APR 16, 2015", "APR 16, 2015", "APR 14, 2015", "APR 14, 2015", "APR 13, 2015", "APR 13, 2015", "APR 10, 2015", "APR 16, 2015", "APR 7, 2015", "APR 6, 2015", "APR 1, 2015", "MAR 30, 2015", "MAR 27, 2015", "MAR 26, 2015", "MAR 26, 2015", "APR 9, 2015", "MAR 24, 2015", "MAR 23, 2015", "MAR 23, 2015", "MAR 23, 2015", "MAR 20, 2015", "MAR 20, 2015", "MAR 20, 2015", "MAR 25, 2015", "MAR 18, 2015", "MAR 18, 2015", "MAR 16, 2015", "MAR 16, 2015", "MAR 13, 2015", "MAR 13, 2015", "MAR 13, 2015", "MAR 19, 2015", "MAR 18, 2015", "MAR 9, 2015", "MAR 9, 2015", "MAR 6, 2015", "MAR 4, 2015", "MAR 3, 2015", "MAR 3, 2015", "MAR 13, 2015", "MAR 2, 2015", "MAR 2, 2015", "MAR 2, 2015", "MAR 2, 2015", "FEB 28, 2015", "FEB 27, 2015", "FEB 26, 2015", "MAR 3, 2015", "FEB 24, 2015", "FEB 20, 2015", "DEC 30, 2014", "DEC 30, 2014", "DEC 30, 2014", "DEC 23, 2014", "DEC 23, 2014", "FEB 25, 2015", "FEB 24, 2015", "FEB 20, 2015", "DEC 18, 2014", "DEC 16, 2014", "DEC 16, 2014", "DEC 16, 2014", "DEC 16, 2014", "DEC 23, 2014", "DEC 16, 2014", "DEC 15, 2014", "DEC 15, 2014", "DEC 15, 2014", "DEC 12, 2014", "DEC 12, 2014", "DEC 12, 2014", "DEC 16, 2014", "DEC 11, 2014", "DEC 10, 2014", "DEC 10, 2014", "DEC 10, 2014", "DEC 10, 2014", "DEC 9, 2014", "DEC 9, 2014", "DEC 11, 2014", "DEC 11, 2014", "DEC 10, 2014", "DEC 5, 2014", "DEC 5, 2014", "DEC 5, 2014", "DEC 5, 2014", "DEC 8, 2014", "DEC 4, 2014", "DEC 4, 2014", "DEC 4, 2014", "DEC 4, 2014", "DEC 3, 2014", "DEC 3, 2014", "DEC 3, 2014", "DEC 4, 2014", "NOV 28, 2014", "NOV 28, 2014", "NOV 26, 2014", "NOV 26, 2014", "NOV 25, 2014", "NOV 25, 2014", "NOV 21, 2014", "NOV 28, 2014", "NOV 21, 2014", "NOV 21, 2014", "NOV 21, 2014", "NOV 20, 2014", "NOV 19, 2014", "NOV 19, 2014", "NOV 19, 2014", "NOV 21, 2014", "NOV 18, 2014", "NOV 18, 2014", "NOV 17, 2014", "NOV 17, 2014", "NOV 17, 2014", "NOV 14, 2014", "NOV 13, 2014", "NOV 18, 2014", "NOV 12, 2014", "NOV 7, 2014", "NOV 6, 2014", "NOV 6, 2014", "NOV 3, 2014", "OCT 24, 2014", "OCT 6, 2014", "NOV 13, 2014", "AUG 5, 2014", "AUG 4, 2014", "AUG 4, 2014", "JUL 8, 2014", "JUL 7, 2014", "JUL 3, 2014", "JUL 3, 2014", "SEP 2, 2014", "JUL 2, 2014", "JUL 1, 2014", "JUL 1, 2014", "JUL 1, 2014", "JUL 1, 2014", "JUL 1, 2014", "JUN 30, 2014", "JUL 2, 2014", "JUN 30, 2014", "JUN 30, 2014", "JUN 30, 2014", "JUN 27, 2014", "JUN 27, 2014", "JUN 26, 2014", "JUN 26, 2014", "JUN 30, 2014", "JUN 24, 2014", "JUN 23, 2014", "JUN 23, 2014", "JUN 19, 2014", "JUN 19, 2014", "JUN 19, 2014", "JUN 19, 2014", "JUN 25, 2014", "JUN 19, 2014", "JUN 18, 2014", "JUN 17, 2014", "JUN 17, 2014", "JUN 17, 2014", "JUN 17, 2014", "JUN 16, 2014", "JUN 19, 2014", "JUN 16, 2014", "JUN 13, 2014", "JUN 13, 2014", "JUN 13, 2014", "JUN 13, 2014", "JUN 12, 2014", "JUN 12, 2014", "JUN 16, 2014", "JUN 12, 2014", "JUN 12, 2014", "JUN 12, 2014", "JUN 12, 2014", "JUN 12, 2014", "JUN 12, 2014", "JUN 12, 2014", "JUN 12, 2014", "JUN 11, 2014", "JUN 10, 2014", "JUN 10, 2014", "JUN 10, 2014", "JUN 10, 2014", "JUN 10, 2014", "JUN 10, 2014", "JUN 11, 2014", "JUN 9, 2014", "JUN 9, 2014", "JUN 9, 2014", "JUN 6, 2014", "JUN 6, 2014", "JUN 6, 2014", "JUN 5, 2014", "JUN 10, 2014", "JUN 4, 2014", "JUN 3, 2014", "JUN 3, 2014", "JUN 3, 2014", "JUN 2, 2014", "JUN 2, 2014", "MAY 30, 2014", "JUN 5, 2014", "MAY 30, 2014", "MAY 29, 2014", "MAY 29, 2014", "MAY 28, 2014", "MAY 28, 2014", "MAY 27, 2014", "MAY 22, 2014", "MAY 30, 2014", "MAY 21, 2014", "MAY 21, 2014", "MAY 21, 2014", "MAY 21, 2014", "MAY 20, 2014", "MAY 19, 2014", "MAY 16, 2014", "MAY 21, 2014", "MAY 15, 2014", "MAY 15, 2014", "MAY 14, 2014", "MAY 14, 2014", "MAY 14, 2014", "MAY 14, 2014", "MAY 13, 2014", "MAY 16, 2014", "MAY 12, 2014", "MAY 12, 2014", "MAY 9, 2014", "MAY 9, 2014", "MAY 8, 2014", "APR 21, 2014", "APR 17, 2014", "MAY 12, 2014", "APR 16, 2014", "APR 11, 2014", "APR 11, 2014", "APR 11, 2014", "APR 11, 2014", "APR 11, 2014", "APR 8, 2014", "APR 17, 2014", "APR 16, 2014", "APR 8, 2014", "APR 4, 2014", "APR 3, 2014", "APR 1, 2014", "MAR 28, 2014", "MAR 28, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "MAR 24, 2014", "MAR 21, 2014", "MAR 21, 2014", "MAR 21, 2014", "MAR 20, 2014", "MAR 28, 2014", "MAR 27, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 14, 2014", "MAR 14, 2014", "MAR 11, 2014", "FEB 25, 2014", "MAR 20, 2014", "DEC 30, 2013", "DEC 30, 2013", "FEB 18, 2014"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/why-the-fdas-drug-competition-action-plan-is-bad-news-for-generic-pharmaceutical-stocks", "https://www.nasdaq.com/articles/ani-pharmaceuticals-inc-anip-q1-2020-earnings-call-transcript-2020-05-08", "https://www.nasdaq.com/articles/ani-pharmaceuticals-q1-20-earnings-conference-call-at-10%3A30-am-et-2020-05-07", "https://www.nasdaq.com/articles/ani-pharma-suspends-guidance-appoints-patrick-walsh-as-interim-president-ceo-2020-05-07", "https://www.nasdaq.com/articles/ani-pharmaceuticals-inc.-q1-adjusted-earnings-beat-estimates-2020-05-07", "https://www.nasdaq.com/articles/ani-gets-refusal-to-file-letter-for-cortrophin-gel-seeks-meeting-with-fda-2020-04-29", "https://www.nasdaq.com/articles/how-ani-pharmaceuticals-plans-to-take-down-a-price-gouging-giant-2020-04-17", "https://www.nasdaq.com/articles/notable-wednesday-option-activity%3A-qcom-now-anip-2020-04-15", "https://www.nasdaq.com/articles/why-the-fdas-drug-competition-action-plan-is-bad-news-for-generic-pharmaceutical-stocks", "https://www.nasdaq.com/articles/ani-pharma-launches-omega-3-acid-ethyl-esters-capsules-quick-facts-2020-04-02", "https://www.nasdaq.com/articles/ani-pharmaceuticals-inc-anip-q4-2019-earnings-call-transcript-2020-02-28", "https://www.nasdaq.com/articles/ani-pharmaceuticals-q4-19-earnings-conference-call-at-10%3A30-am-et-2020-02-27", "https://www.nasdaq.com/articles/ani-pharma-guides-fy20-below-estimates-quick-facts-2020-02-27", "https://www.nasdaq.com/articles/ani-pharmaceuticals-inc.-q4-adjusted-earnings-miss-estimates-2020-02-27", "https://www.nasdaq.com/articles/ani-pharma-launches-sulfamethoxazole-trimethoprim-oral-suspension-2020-02-12", "https://www.nasdaq.com/articles/commit-to-buy-ani-pharmaceuticals-at-%2455-earn-13-annualized-using-options-2020-02-10", "https://www.nasdaq.com/articles/ani-pharmaceuticals-ceo-arthur-przybyl-to-depart-on-may-10-quick-facts-2020-04-14", "https://www.nasdaq.com/articles/ani-pharma-acquires-u.s.-portfolio-of-23-generic-products-from-amerigen-2020-01-09", "https://www.nasdaq.com/articles/ani-pharma-to-present-at-evercore-isi-healthconx-conference-webcast-at-10%3A15-am-2019-12-03", "https://www.nasdaq.com/articles/ani-pharmaceuticals-inc.-q3-adjusted-earnings-miss-estimates-2019-11-06", "https://www.nasdaq.com/articles/ani-pharma-reports-positive-results-from-cortrophin-gel-cortisol-response-study-2019-10-03", "https://www.nasdaq.com/articles/ani-pharmaceuticals-inc-anip-q2-2019-earnings-call-transcript-2019-08-07", "https://www.nasdaq.com/articles/ani-pharmaceuticals-is-now-oversold-anip-2019-08-07", "https://www.nasdaq.com/articles/ani-pharmaceuticals-inc.-q2-adjusted-earnings-beat-estimates-2019-08-07", "https://www.nasdaq.com/articles/ani-pharma-%3A-fda-okays-potassium-citrate-extended-release-tablets-usp-2020-01-16", "https://www.nasdaq.com/articles/ani-pharmaceuticals-q1-19-earnings-conference-call-10%3A30-am-et-2019-05-09", "https://www.nasdaq.com/articles/ani-pharmaceuticals-inc.-q1-adjusted-earnings-beat-estimates-2019-05-09", "https://www.nasdaq.com/articles/commit-purchase-ani-pharmaceuticals-60-earn-8.1-annualized-using-options-2019-05-06", "https://www.nasdaq.com/articles/ani-pharmaceuticals-anip-stock-sinks-as-market-gains%3A-what-you-should-know-2019-04-18", "https://www.nasdaq.com/articles/ultragenyxs-rare-ux007-gets-fast-track-status-by-fda-2019-04-17", "https://www.nasdaq.com/articles/ani-pharmaceuticals-anip-outpaces-stock-market-gains%3A-what-you-should-know-2019-04-12-0", "https://www.nasdaq.com/articles/ani-pharmaceuticals-anip-stock-sinks-as-market-gains%3A-what-you-should-know-2019-04-05-0", "https://www.nasdaq.com/articles/ani-pharmaceuticals-inc-anip-q1-2019-earnings-call-transcript-2019-05-10", "https://www.nasdaq.com/articles/3-under-radar-value-stocks-buy-2019-2019-01-01", "https://www.nasdaq.com/articles/3-top-small-cap-stocks-buy-right-now-2018-11-30", "https://www.nasdaq.com/articles/is-ani-pharmaceuticals-a-great-stock-for-value-investors-2018-11-20", "https://www.nasdaq.com/articles/ani-pharmaceuticals-inc-anip-q3-2018-earnings-conference-call-transcript-2018-11-06", "https://www.nasdaq.com/articles/zacks-industry-outlook-highlights%3A-amgen-ani-and-illumina-2018-07-06", "https://www.nasdaq.com/articles/dermira-derm-gains-5-in-a-week-post-qbrexa-approval-2018-07-06", "https://www.nasdaq.com/articles/sareptas-dmd-portfolio-solid-sole-drug-dependence-concerns-2018-07-05", "https://www.nasdaq.com/articles/ani-pharmaceuticals-anip-q4-2018-earnings-conference-call-transcript-2019-02-28", "https://www.nasdaq.com/articles/juniper-inks-deal-to-be-acquired-by-catalent-shares-up-2018-07-04", "https://www.nasdaq.com/articles/alkermes-aristada-initio-approved-by-fda-for-schizophrenia-2018-07-03", "https://www.nasdaq.com/articles/roches-breast-cancer-study-meets-co-primary-endpoint-2018-07-03", "https://www.nasdaq.com/articles/keryx-kerx-inks-merger-deal-with-akebia-shares-fall-2018-06-29", "https://www.nasdaq.com/articles/celgenes-luspatercept-meets-primary-endpoint-in-the-study-2018-06-29", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-snda-for-xyrem-gets-priority-review-2018-06-28", "https://www.nasdaq.com/articles/medicines-companys-inclisiran-studies-to-continue-unmodified-2018-06-28", "https://www.nasdaq.com/articles/biotech-stock-outlook%3A-short-term-pricing-pain-to-prevail-2018-07-05", "https://www.nasdaq.com/articles/lillys-diabetes-drugs-meet-endpoints-in-phase-iii-studies-2018-06-26", "https://www.nasdaq.com/articles/roches-rhhby-flu-candidate-gets-priority-review-by-the-fda-2018-06-26", "https://www.nasdaq.com/articles/pfizers-breast-cancer-drug-misses-overall-survival-in-study-2018-06-26", "https://www.nasdaq.com/articles/merrimack-crashes-as-phase-ii-pancreatic-cancer-study-fails-2018-06-26", "https://www.nasdaq.com/articles/novo-nordisk-nvo-announces-results-in-diabetes-studies-2018-06-25", "https://www.nasdaq.com/articles/anika-reports-top-line-data-from-cingal-study-shares-slump-2018-06-21", "https://www.nasdaq.com/articles/puma-biotechnologys-shares-rise-on-positive-chmp-trend-vote-2018-06-27", "https://www.nasdaq.com/articles/alexion-alxn-submits-application-for-alxn1210-with-fda-2018-06-20", "https://www.nasdaq.com/articles/agios-agio-initiates-phase-iii-study-on-pk-deficiency-drug-2018-06-20", "https://www.nasdaq.com/articles/roche-to-buy-rest-of-foundation-medicine-for-%242.4-billion-2018-06-20", "https://www.nasdaq.com/articles/4-undervalued-medtech-stocks-to-consider-amid-volatility-2018-06-19", "https://www.nasdaq.com/articles/4-undervalued-medtech-stocks-to-consider-amid-volatility-2018-06-19-0", "https://www.nasdaq.com/articles/sarepta-inks-manufacturing-deal-for-gene-therapy-program-2018-06-14", "https://www.nasdaq.com/articles/flex-pharma-down-on-workforce-reduction-ends-phase-ii-study-2018-06-14", "https://www.nasdaq.com/articles/novo-nordisk-in-deal-with-kallyope-for-obesity-diabetes-drugs-2018-06-20", "https://www.nasdaq.com/articles/alexion-alxn-submits-application-for-alxn1210-with-fda-2018-06-20", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-lgnd-hits-a-52-week-high-can-the-run-continue-2018-05-21", "https://www.nasdaq.com/articles/should-value-investors-pick-ani-pharmaceuticals-anip-stock-2018-03-14", "https://www.nasdaq.com/articles/mylan-trying-close-key-technical-measure-2018-02-02", "https://www.nasdaq.com/articles/perrigo-clears-key-benchmark-hitting-80-plus-rs-rating-2018-01-26", "https://www.nasdaq.com/articles/how-hospitals-plan-put-pressure-generic-drug-makers-2018-01-18", "https://www.nasdaq.com/articles/heres-why-sarepta-is-up-more-than-60-so-far-this-year-2018-05-29", "https://www.nasdaq.com/articles/biomarins-palynziq-gets-fda-approval-for-phenylketonuria-2018-05-25", "https://www.nasdaq.com/articles/insys-gets-negative-fda-recommendation-for-pain-candidate-2018-05-23", "https://www.nasdaq.com/articles/mylan-sees-rs-rating-improve-75-2018-01-05", "https://www.nasdaq.com/articles/stocks-generating-improved-relative-strength-lannett-2018-01-04", "https://www.nasdaq.com/articles/stocks-showing-rising-market-leadership-insys-therapeutics-earns-89-rs-rating-2018-01-04", "https://www.nasdaq.com/articles/top-rated-stocks-ani-pharmaceuticals-sees-composite-rating-climb-97-2018-01-03", "https://www.nasdaq.com/articles/perrigo-getting-closer-key-technical-benchmark-2018-01-03", "https://www.nasdaq.com/articles/mylan-hits-80-plus-relative-strength-rating-benchmark-2018-01-12", "https://www.nasdaq.com/articles/perrigo-trying-close-key-technical-benchmark-2018-01-11", "https://www.nasdaq.com/articles/stocks-watch-ani-pharmaceuticals-sees-relative-strength-rating-rise-93-2017-11-29", "https://www.nasdaq.com/articles/spectrum-doubles-in-3-months%3A-whats-driving-the-rally-2017-11-27", "https://www.nasdaq.com/articles/ani-pharmaceuticals-anip-catches-eye%3A-stock-jumps-17.7-2017-11-27", "https://www.nasdaq.com/articles/stocks-showing-market-leadership-collegium-pharmaceutical-earns-91-rs-rating-2017-11-16", "https://www.nasdaq.com/articles/taro-pharmaceutical-industries-earns-rs-rating-upgrade-2017-11-13", "https://www.nasdaq.com/articles/pfizer-hikes-dividend-announces-%2410b-share-buyback-plan-2017-12-19", "https://www.nasdaq.com/articles/perrigo-gets-technical-rating-upgrade-2017-11-07", "https://www.nasdaq.com/articles/3-small-profitable-biotechs-fantastic-growth-2017-10-24", "https://www.nasdaq.com/articles/anip-crosses-above-average-analyst-target-2017-10-16", "https://www.nasdaq.com/articles/perrigo-sees-ibd-rs-rating-improve-73-2017-10-11", "https://www.nasdaq.com/articles/3-top-small-cap-stocks-buy-august-2017-08-21", "https://www.nasdaq.com/articles/4-top-small-cap-stocks-buy-june-2017-06-12", "https://www.nasdaq.com/articles/4-cheapest-biotech-stocks-world-2017-05-11", "https://www.nasdaq.com/articles/lannett-joins-elite-club-stocks-rs-ratings-over-90-2017-11-08", "https://www.nasdaq.com/articles/pre-market-earnings-report-march-2-2017-cnq-kr-bud-burl-joy-aciw-mei-anf-dea-bks-anip-sup", "https://www.nasdaq.com/articles/4-top-small-cap-stocks-buy-winter-2017-01-23", "https://www.nasdaq.com/articles/5-growth-stocks-could-double-2017-01-07", "https://www.nasdaq.com/articles/thursday-sector-laggards-music-electronics-stores-drugs-2016-11-03", "https://www.nasdaq.com/articles/ocular-begins-enrollment-in-phase-iii-trial-on-glaucoma-drug-2016-10-05", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-vivus-geron-achillion-pharmaceuticals-anika", "https://www.nasdaq.com/articles/teva-boosts-generic-business-with-allergan-anda-takeover-2016-10-04", "https://www.nasdaq.com/articles/moving-average-crossover-alert%3A-ani-pharmaceuticals-anip-2017-03-13", "https://www.nasdaq.com/articles/abbvie%3A-hcv-regimen-obtains-breakthrough-therapy-status-2016-10-03", "https://www.nasdaq.com/articles/immunogen-to-cut-workforce-by-17-for-long-term-growth-2016-10-03", "https://www.nasdaq.com/articles/endo-international-reports-positive-phase-ii-data-on-xiaflex-2016-10-03", "https://www.nasdaq.com/articles/pain-therapeutics-ptie-down-crl-chronic-pain-drug-2016-09-28", "https://www.nasdaq.com/articles/jazz-pharma-closes-enrollment-in-osa-drug-phase-iii-trial-2016-09-28", "https://www.nasdaq.com/articles/acelrx-acrx-initiates-phase-iii-iap312-study-on-zalviso-2016-09-28", "https://www.nasdaq.com/articles/juno-therapeutics-juno-catches-eye%3A-stock-jumps-13-2016-09-28", "https://www.nasdaq.com/articles/vivus-licenses-stendra-rights-to-metuchen-pharmaceuticals-2016-10-04", "https://www.nasdaq.com/articles/abbvie-abbv-files-snda-for-blood-cancer-drug-imbruvica-2016-09-27", "https://www.nasdaq.com/articles/amarin-corporation-amrn-looks-good%3A-stock-adds-6.1-in-session-2016-09-27", "https://www.nasdaq.com/articles/achillion-jj-hcv-triple-combination-drug-data-presented-2016-09-26", "https://www.nasdaq.com/articles/abbvie-abbv-hcv-combination-drug-positive-in-phase-iiib-2016-09-26", "https://www.nasdaq.com/articles/strength-seen-in-newlink-genetics-nlnk%3A-stock-jumps-5-2016-09-26", "https://www.nasdaq.com/articles/biotime-btx-shows-strength%3A-stock-adds-5.9-in-session-2016-09-26", "https://www.nasdaq.com/articles/ligand-inks-cns-license-agreement-with-seelos-therapeutics-2016-09-23", "https://www.nasdaq.com/articles/amgens-multiple-myeloma-drug-kyprolis-fails-in-phase-iii-2016-09-28", "https://www.nasdaq.com/articles/astrazeneca-withdraws-cediranib-marketing-application-in-eu-2016-09-22", "https://www.nasdaq.com/articles/the-medicines-co.-to-get-barda-funding-for-infection-drugs-2016-09-22", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-drna-worth-a-look%3A-stock-up-6-2016-09-22", "https://www.nasdaq.com/articles/puma-pbyi-neratinibs-nda-accepted-for-review-stock-up-2016-09-21", "https://www.nasdaq.com/articles/amgen-amgn-repatha-meets-endpoints-in-phase-iii-study-2016-09-21", "https://www.nasdaq.com/articles/bristol-myers-opdivos-regulatory-application-validated-in-eu-2016-09-21", "https://www.nasdaq.com/articles/adamas-adms-parkinsons-disease-drug-positive-in-phase-iii-2016-09-21", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-ani-pharmaceuticals-stoneridge-cooper-standard-holdings", "https://www.nasdaq.com/articles/regenxbio-rgnx-worth-watching%3A-stock-adds-5.3-in-session-2016-09-21", "https://www.nasdaq.com/articles/regeneron-teva-collaborate-to-develop-chronic-pain-drug-2016-09-21", "https://www.nasdaq.com/articles/biodelivery-bunavail-gets-better-managed-care-positioning-2016-09-20", "https://www.nasdaq.com/articles/sarepta-stock-nearly-doubles-on-fda-approval-for-dmd-drug-2016-09-20", "https://www.nasdaq.com/articles/bayer-bayry-strives-for-increased-sales-earnings-growth-2016-09-20", "https://www.nasdaq.com/articles/cara-therapeutics-cara-catches-eye%3A-stock-rises-5.7-2016-09-20", "https://www.nasdaq.com/articles/colucid-pharmaceuticals-clcd-in-focus%3A-stock-jumps-7.4-2016-09-20", "https://www.nasdaq.com/articles/proqr-therapeutics-prqr-catches-eye%3A-stock-rises-8.2-2016-09-21", "https://www.nasdaq.com/articles/celgene-presents-efficacy-safety-phase-ii-ozanimod-data-2016-09-20", "https://www.nasdaq.com/articles/vical-slumps-cytomegalovirus-vaccine-fails-in-phase-ii-study-2016-09-20", "https://www.nasdaq.com/articles/amgen-amgn-parsabiv-gets-positive-chmp-opinion-in-eu-2016-09-19", "https://www.nasdaq.com/articles/astrazeneca-diabetes-drug-combination-positive-in-phase-iii-2016-09-19", "https://www.nasdaq.com/articles/ligand-lgnd-inks-deal-with-teneobio-for-omniab-technology-2016-09-19", "https://www.nasdaq.com/articles/eli-lilly-lly-gets-favorable-chmp-opinion-for-olaratumab-2016-09-19", "https://www.nasdaq.com/articles/novartis-nvs-presents-positive-data-on-cardiovascular-drug-2016-09-19", "https://www.nasdaq.com/articles/idera-pharmaceuticals-in-focus%3A-stock-adds-8.8-in-session-2016-09-20", "https://www.nasdaq.com/articles/masimo-pvi%3A-efficient-predictor-for-fluid-optimization-2016-09-16", "https://www.nasdaq.com/articles/qiagen%3A-molecular-diagnostics-expansion-plans-on-track-2016-09-16", "https://www.nasdaq.com/articles/novavax-tanks-rsv-f-vaccine-disappoints-in-two-studies-2016-09-16", "https://www.nasdaq.com/articles/merck-pfizer-diabetes-drug-ertugliflozin-positive-in-phase-iii-2016-09-16", "https://www.nasdaq.com/articles/teva-intel-tie-up-for-huntingtons-disease-technology-platform-2016-09-16", "https://www.nasdaq.com/articles/glaxo-gsk-publishes-phase-iii-data-on-shingles-vaccine-2016-09-15", "https://www.nasdaq.com/articles/novo-nordisk-nvo-presents-data-on-obesity-drug-saxenda-2016-09-15", "https://www.nasdaq.com/articles/halozyme-therapeutics-halo-catches-eye%3A-stock-up-7.9-2016-09-19", "https://www.nasdaq.com/articles/bayer-to-boost-agriculture-suite-with-%2466b-monsanto-buyout-2016-09-15", "https://www.nasdaq.com/articles/aerie-aeri-stock-up-on-positive-phase-iii-data-on-roclatan-2016-09-15", "https://www.nasdaq.com/articles/shires-immunodeficiency-treatment-cuvitru-gets-fda-approval-2016-09-15", "https://www.nasdaq.com/articles/asterias-biotherapeutics-ast-catches-eye%3A-stock-jumps-6-2016-09-15", "https://www.nasdaq.com/articles/allergan-to-buy-vitae-pharma-to-boost-dermatology-suite-2016-09-15", "https://www.nasdaq.com/articles/spectrum-sppi-down-qapzola-fails-to-impress-fda-panel-2016-09-15", "https://www.nasdaq.com/articles/sarepta-shares-soar-on-news-of-key-drug-critic-fda-exit-2016-09-15", "https://www.nasdaq.com/articles/roche-ocrevus-positive-in-phase-iii-multiple-sclerosis-trials-2016-09-15", "https://www.nasdaq.com/articles/ani-pharmaceuticals-anip-sees-hammer-chart-pattern-time-to-buy-2016-09-14", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-mylan-ani-pharmaceuticals-cambrex-pdl-biopharma-and", "https://www.nasdaq.com/articles/ligand-lgnd-commences-phase-ii-type-ii-diabetes-study-2016-09-14", "https://www.nasdaq.com/articles/sanofi-sny-presents-positive-diabetes-data-on-iglarlixi-2016-09-14", "https://www.nasdaq.com/articles/will-bayer-bayry-raise-its-monsanto-buyout-offer-again-2016-09-14", "https://www.nasdaq.com/articles/glaxo-jj-file-for-rheumatoid-arthritis-drug-sirukumab-in-eu-2016-09-13", "https://www.nasdaq.com/articles/geron-gern-at-52-week-low-on-imetelstat-study-update-2016-09-13", "https://www.nasdaq.com/articles/sanofi-sny-presents-positive-diabetes-data-iglarlixi-revised-2016-09-15", "https://www.nasdaq.com/articles/celgenes-crohns-disease-drug-positive-in-phase-ib-study-2016-09-13", "https://www.nasdaq.com/articles/reata-pharmaceuticals-reta-jumps%3A-stock-rises-13.2-2016-09-13", "https://www.nasdaq.com/articles/4-biotech-stocks-buy-election-fever-rises-2016-09-13", "https://www.nasdaq.com/articles/xencor-xncr-doses-first-patient-in-myeloid-leukemia-trial-2016-09-13", "https://www.nasdaq.com/articles/tesaro-gets-fast-track-designation-for-ovarian-cancer-drug-2016-09-13", "https://www.nasdaq.com/articles/auris-ears-advances-on-sudden-deafness-study-stock-up-2016-09-12", "https://www.nasdaq.com/articles/achillion-jjs-hcv-combo-drug-positive-in-phase-iia-trial-2016-09-12", "https://www.nasdaq.com/articles/repros-seeks-eu-approval-for-secondary-hypogonadism-drug-2016-09-13", "https://www.nasdaq.com/articles/bluebird-bio-stock-up-on-start-of-phase-iii-lentiglobin-study-2016-09-09", "https://www.nasdaq.com/articles/epizyme-non-hodgkin-lymphoma-drug-clears-futility-hurdle-2016-09-08", "https://www.nasdaq.com/articles/alnylam-alny-reports-positive-phase-i-data-on-aln-as1-2016-09-08", "https://www.nasdaq.com/articles/repros-therapeutics-rprx-proellex-positive-in-phase-ii-2016-09-08", "https://www.nasdaq.com/articles/dynavax-rebounds-on-same-pdufa-date-for-heplisav-bla-2016-09-07", "https://www.nasdaq.com/articles/colucid-hits-52-week-high-on-positive-data-on-migraine-drug-2016-09-07", "https://www.nasdaq.com/articles/exelixis-reports-interim-analysis-of-liver-cancer-trial-data-2016-09-07", "https://www.nasdaq.com/articles/asterias-biotherapeutics-ast-soars%3A-stock-rises-by-10.9-2016-09-12", "https://www.nasdaq.com/articles/masimo-amends-nellcors-pulse-oximetry-royalty-agreement-2016-09-06", "https://www.nasdaq.com/articles/novartis-nvs-reports-positive-data-on-ultibro-breezhaler-2016-09-06", "https://www.nasdaq.com/articles/bayer-bayry-raises-offer-to-purchase-monsanto-yet-again-2016-09-06", "https://www.nasdaq.com/articles/catalyst-firdapse-gets-orphan-status-for-myasthenia-gravis-2016-09-06", "https://www.nasdaq.com/articles/astrazeneca-azn-presents-benralizumab-phase-iii-data-2016-09-06", "https://www.nasdaq.com/articles/compugen-cgen-looks-good%3A-stock-adds-5.1-in-session-2016-09-06", "https://www.nasdaq.com/articles/myriad-genetics-adds-assurex-health-grows-in-neuroscience-2016-09-06", "https://www.nasdaq.com/articles/glaxo-bexsero-meningitis-b-immunization-shows-positive-data-2016-09-06", "https://www.nasdaq.com/articles/novo-nordisks-ideglira-review-period-extended-in-the-u.s.-2016-09-05", "https://www.nasdaq.com/articles/merck-stops-development-of-odanacatib-for-osteoporosis-2016-09-05", "https://www.nasdaq.com/articles/mylan-myl-gets-positive-copaxone-uspto-ruling-yet-again-2016-09-02", "https://www.nasdaq.com/articles/arena-arna-beacon-discovery-to-boost-research-platform-2016-09-02", "https://www.nasdaq.com/articles/amgen-gets-fda-approval-for-label-expansion-of-blincyto-2016-09-02", "https://www.nasdaq.com/articles/roche-immuno-oncology-drug-tecentriq-positive-in-phase-iii-2016-09-01", "https://www.nasdaq.com/articles/amarin-amrn-ends-patient-randomization-in-vascepa-study-2016-09-01", "https://www.nasdaq.com/articles/mylans-epipen-misclassified-rebates-underpaid-stock-down-2016-09-05", "https://www.nasdaq.com/articles/pfizers-lung-cancer-drug-xalkori-label-expanded-in-the-eu-2016-09-01", "https://www.nasdaq.com/articles/array-arry-presents-positive-cardiovascular-trial-data-2016-08-31", "https://www.nasdaq.com/articles/express-scripts-new-program-to-lower-diabetes-care-costs-2016-08-31", "https://www.nasdaq.com/articles/ariad-finishes-rolling-nda-for-lung-cancer-drug-brigatinib-2016-08-31", "https://www.nasdaq.com/articles/orexigen-stock-up-on-commercialization-deal-for-contrave-2016-08-31", "https://www.nasdaq.com/articles/rigel-rigl-stock-up-on-positive-phase-iii-fostamatinib-data-2016-08-31", "https://www.nasdaq.com/articles/colucid-pharmaceuticals-clcd-jumps%3A-stock-rises-12.1-2016-08-31", "https://www.nasdaq.com/articles/what-makes-editas-medicine-edit-a-strong-sell-2016-09-01", "https://www.nasdaq.com/articles/alexions-gvhd-candidate-gets-orphan-drug-status-in-the-eu-2016-08-30", "https://www.nasdaq.com/articles/amgen-amgn-reports-positive-data-on-prolia-and-repatha-2016-08-30", "https://www.nasdaq.com/articles/inovio-stock-up-as-second-zika-virus-vaccine-study-begins-2016-08-30", "https://www.nasdaq.com/articles/macrocure-stock-up-on-merger-deal-with-leap-therapeutics-2016-08-30", "https://www.nasdaq.com/articles/weeks-hidden-gems-amwdanip-2016-08-30", "https://www.nasdaq.com/articles/regeneron-sanofi-present-positive-phase-iii-praluent-data-2016-08-29", "https://www.nasdaq.com/articles/roche-gets-fda-nod-for-emergency-use-of-zika-virus-test-2016-08-29", "https://www.nasdaq.com/articles/cti-biopharma-reports-mixed-pacritinib-study-data-stock-up-2016-08-30", "https://www.nasdaq.com/articles/mallinckrodt-dmd-drug-gets-fast-track-status-in-the-u.s.-2016-08-26", "https://www.nasdaq.com/articles/vanda-stock-up-on-favorable-u.s.-court-ruling-for-fanapt-2016-08-26", "https://www.nasdaq.com/articles/mylan-myl-obtains-favorable-uspto-ruling-for-copaxone-2016-08-25", "https://www.nasdaq.com/articles/amgen-gets-crl-for-secondary-hyperparathyroidism-drug-2016-08-25", "https://www.nasdaq.com/articles/kindred-biosciences-kin-jumps%3A-stock-moves-5.7-higher-2016-08-25", "https://www.nasdaq.com/articles/urban-outfitters-fogo-de-chao-oclaro-ani-pharmaceuticals-and-formfactor-highlighted-as", "https://www.nasdaq.com/articles/mylan-myl-draws-flak-for-over-pricing-epipen-stock-down-2016-08-24", "https://www.nasdaq.com/articles/abbott-labs-sued-by-alere-over-pending-%245.8b-acquisition-2016-08-29", "https://www.nasdaq.com/articles/mallinckrodt-dmd-drug-gets-fast-track-status-in-the-u.s.-2016-08-26", "https://www.nasdaq.com/articles/regeneron-stock-up-on-barda-deal-for-mers-antibodies-2016-08-23", "https://www.nasdaq.com/articles/roche-launches-accu-chek-blood-glucose-monitoring-system-2016-08-23", "https://www.nasdaq.com/articles/galapagos-glpg-advances-ra-drug-filgotinib-to-phase-iii-2016-08-23", "https://www.nasdaq.com/articles/puma-pbyi-neratinibs-application-validated-in-eu-stock-up-2016-08-23", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-ani-pharmaceuticals-cooper-standard-holdings-berry-plastics", "https://www.nasdaq.com/articles/3-small-cap-stocks-sky-high-growth-potential-2016-08-23", "https://www.nasdaq.com/articles/pfizer-to-acquire-rights-to-astrazenecas-antibiotics-business-2016-08-24", "https://www.nasdaq.com/articles/editas-medicine-edit-in-focus%3A-stock-moves-5.1-higher-2016-08-22", "https://www.nasdaq.com/articles/xenetics-ind-to-start-phase-ii-virexxa-study-accepted-in-u.s.-2016-08-22", "https://www.nasdaq.com/articles/portola-indexxas-regulatory-application-validated-in-the-eu-2016-08-22", "https://www.nasdaq.com/articles/pfizers-pfe-pain-drug-troxyca-er-receives-fda-approval-2016-08-22", "https://www.nasdaq.com/articles/horizon-hznp-rayos-receives-uspto-notice-of-allowance-2016-08-19", "https://www.nasdaq.com/articles/aclaris-acrs-common-warts-candidate-positive-in-phase-ii-2016-08-19", "https://www.nasdaq.com/articles/fda-oks-edwards-lifesciences-sapien-3-for-extended-use-2016-08-19", "https://www.nasdaq.com/articles/supernus-trokendi-xr-gets-fda-nod-for-migraine-in-adults-2016-08-22", "https://www.nasdaq.com/articles/intercept-icpt-ocaliva-phase-iii-poise-data-published-2016-08-18", "https://www.nasdaq.com/articles/cerulean-ceru-kidney-cancer-drug-disappoints-in-phase-ii-2016-08-18", "https://www.nasdaq.com/articles/why-ani-pharmaceuticals-anip-could-be-positioned-for-a-surge-2016-08-18", "https://www.nasdaq.com/articles/sunesis-pharmaceuticals-snss-jumps%3A-stock-rises-23.1-2016-08-18", "https://www.nasdaq.com/articles/oncogenex-down-on-poor-phase-iii-data-on-lead-cancer-drug-2016-08-17", "https://www.nasdaq.com/articles/how-ani-pharmaceuticals-anip-stock-stands-out-in-a-strong-industry-2016-08-17", "https://www.nasdaq.com/articles/actelion-aliof-uptravi-approved-for-pah-in-switzerland-2016-08-17", "https://www.nasdaq.com/articles/portola-ptla-stock-down-on-crl-for-andexxa-bla-in-u.s.-2016-08-18", "https://www.nasdaq.com/articles/inovio-ino-veterinary-vaccine-rights-licensed-to-plumbline-2016-08-17", "https://www.nasdaq.com/articles/radius-rdus-osteoporosis-drug-positive-in-phase-iii-study-2016-08-17", "https://www.nasdaq.com/articles/align-technologys-invisalign-dependence%3A-boon-or-curse-2016-08-17", "https://www.nasdaq.com/articles/fda-approves-edwards-lifesciences-intuity-elite-heart-valve-2016-08-17", "https://www.nasdaq.com/articles/aurinia-auph-stock-falls-on-poor-phase-ii-lupus-study-data-2016-08-16", "https://www.nasdaq.com/articles/can-the-uptrend-continue-for-ani-pharmaceuticals-anip-2016-08-16", "https://www.nasdaq.com/articles/repros-presents-6-month-interim-data-enclomiphene-2016-08-16", "https://www.nasdaq.com/articles/syros-pharmaceuticals-syrs-jumps%3A-stock-moves-up-36.1-2016-08-17", "https://www.nasdaq.com/articles/vertex-vrtx-stop-vx-661-ivacaftor-study-stock-down-2016-08-16", "https://www.nasdaq.com/articles/myriad-genetics%3A-q4-hit-by-low-test-revenues-gross-margin-2016-08-16", "https://www.nasdaq.com/articles/bristol-myers-to-reacquire-rights-to-oncology-drug-in-asia-2016-08-15", "https://www.nasdaq.com/articles/myriad-genetics-mygn-in-focus%3A-stock-up-5.6-in-session-2016-08-12", "https://www.nasdaq.com/articles/3-reasons-why-ani-pharmaceuticals-anip-is-a-great-momentum-stock-2016-08-12", "https://www.nasdaq.com/articles/strongbridge-biopharma-sbbp-jumps%3A-stock-moves-up-5.5-2016-08-11", "https://www.nasdaq.com/articles/perrigo-prgo-misses-q2-earnings-estimates-cuts-16-view-2016-08-10", "https://www.nasdaq.com/articles/ucb-epilepsy-drug-vimpats-patent-validated-by-u.s.-court-2016-08-16", "https://www.nasdaq.com/articles/catalyst-cprx-reports-narrower-than-expected-q2-loss-2016-08-10", "https://www.nasdaq.com/articles/mylan-beats-on-q2-earnings-revenues-miss-keeps-16-view-2016-08-10", "https://www.nasdaq.com/articles/intrexon-xon-reports-wider-loss-in-q2-revenues-increase-2016-08-10", "https://www.nasdaq.com/articles/aegerion-aegr-q2-loss-wider-than-expected-view-intact-2016-08-10", "https://www.nasdaq.com/articles/gw-pharma-gwph-incurs-narrower-than-expected-q3-loss-2016-08-10", "https://www.nasdaq.com/articles/endo-endp-tops-q2-earnings-estimates-keeps-2016-view-2016-08-09", "https://www.nasdaq.com/articles/fate-therapeutics-fate-jumps%3A-stock-moves-22.8-higher-2016-08-09", "https://www.nasdaq.com/articles/puma-pbyi-posts-narrower-loss-in-q2-focus-on-neratinib-2016-08-10", "https://www.nasdaq.com/articles/celldex-cldx-posts-narrower-q2-loss-focus-pipeline-2016-08-09", "https://www.nasdaq.com/articles/3-top-ranked-growth-stocks-buy-year-2016-08-09", "https://www.nasdaq.com/articles/horizon-hznp-earnings-up-y-y-keeps-16-view-stock-up-2016-08-09", "https://www.nasdaq.com/articles/ani-pharmaceuticals-anip-shares-march-higher-can-it-continue-2016-08-05", "https://www.nasdaq.com/articles/ani-pharmaceuticals-anip-catches-eye%3A-stock-jumps-6.9-2016-08-05", "https://www.nasdaq.com/articles/conatus-cnat-posts-narrower-q2-loss-emricasan-in-focus-2016-08-04", "https://www.nasdaq.com/articles/regeneron-regn-tops-q2-earnings-keeps-16-eylea-view-2016-08-04", "https://www.nasdaq.com/articles/arenas-arna-q2-loss-narrower-revenues-increase-yy-2016-08-09", "https://www.nasdaq.com/articles/aerie-aeri-q2-loss-wider-than-expected-pipeline-in-focus-2016-08-04", "https://www.nasdaq.com/articles/zoetis-zts-beats-on-q2-earnings-revenues-lifts-outlook-2016-08-03", "https://www.nasdaq.com/articles/prothena-prta-reports-wider-than-anticipated-loss-in-q2-2016-08-03", "https://www.nasdaq.com/articles/whats-in-the-cards-for-tripadvisor-trip-in-q2-earnings-2016-08-02", "https://www.nasdaq.com/articles/nivalis-nvls-reports-wider-than-expected-loss-in-q2-2016-08-02", "https://www.nasdaq.com/articles/humana-hum-may-beat-q2-earnings%3A-will-the-stock-gain-2016-08-02", "https://www.nasdaq.com/articles/keryx-kerx-stock-down-on-wider-q2-loss-supply-issues-2016-08-02", "https://www.nasdaq.com/articles/geron-gern-posts-narrower-expected-loss-q2-2016-08-04", "https://www.nasdaq.com/articles/penumbra-pen-to-report-q2-earnings%3A-whats-in-the-cards-2016-08-02", "https://www.nasdaq.com/articles/godaddy-gddy-q2-earnings-likely-to-beat%3A-stock-to-gain-2016-08-01", "https://www.nasdaq.com/articles/can-dentsply-xray-spring-an-earnings-surprise-in-q2-2016-08-01", "https://www.nasdaq.com/articles/will-trovagene-trov-pull-an-earnings-surprise-in-q2-2016-08-01", "https://www.nasdaq.com/articles/inogen-ingn-q2-earnings%3A-can-the-stock-pull-a-surprise-2016-08-01", "https://www.nasdaq.com/articles/pacific-biosciences-pacb-q2-earnings%3A-whats-in-store-2016-08-01", "https://www.nasdaq.com/articles/sanofi-sny-posts-in-line-q2-earnings-revenues-down-y-y-2016-08-01", "https://www.nasdaq.com/articles/22nd-century-group-xxii-catches-eye%3A-stock-rises-7.8-2016-08-02", "https://www.nasdaq.com/articles/aetna-aet-poised-to-beat-on-earnings-in-q2%3A-heres-why-2016-07-29", "https://www.nasdaq.com/articles/alkermes-alks-posts-narrower-q2-loss-ups-2016-outlook-2016-07-29", "https://www.nasdaq.com/articles/agenus-agen-posts-narrower-than-expected-loss-in-q2-2016-07-29", "https://www.nasdaq.com/articles/can-perkinelmer-pki-pull-a-surprise-this-earnings-season-2016-07-29", "https://www.nasdaq.com/articles/astrazeneca-azn-beats-on-q2-earnings-keeps-2016-view-2016-07-29", "https://www.nasdaq.com/articles/becton-dickinson-bdx-q3-earnings%3A-whats-in-the-cards-2016-07-29", "https://www.nasdaq.com/articles/fate-therapeutics-fate-catches-eye%3A-stock-rises-5.9-2016-07-29", "https://www.nasdaq.com/articles/integra-iart-tops-q2-earnings-grows-organically-ups-view-2016-08-01", "https://www.nasdaq.com/articles/can-cerner-cern-spring-a-surprise-this-earnings-season-2016-07-29", "https://www.nasdaq.com/articles/cardinal-health-cah-q4-earnings%3A-disappointment-in-store-2016-07-29", "https://www.nasdaq.com/articles/celgene-celg-tops-q2-earnings-revenues-lifts-view-2016-07-28", "https://www.nasdaq.com/articles/alexion-alxn-tops-q2-earnings-and-revenues-revised-2016-07-28", "https://www.nasdaq.com/articles/glaxo-gsk-beats-q2-earnings-estimates-revenues-up-y-y-2016-07-28", "https://www.nasdaq.com/articles/bristol-myers-bmy-beats-on-q2-earnings-lifts-outlook-2016-07-28", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-bmrn-jumps%3A-stock-rises-6.6-2016-07-28", "https://www.nasdaq.com/articles/eleven-biotherapeutics-ebio-jumps%3A-stock-rises-by-10.4-2016-07-29", "https://www.nasdaq.com/articles/cigna-ci-to-report-q2%3A-will-it-continue-to-beat-estimates-2016-07-28", "https://www.nasdaq.com/articles/vertex-vrtx-posts-narrower-q2-loss-revenues-fall-short-2016-07-28", "https://www.nasdaq.com/articles/curis-cris-in-focus%3A-stock-adds-5.7-in-session-2016-07-27", "https://www.nasdaq.com/articles/eleven-biotherapeutics-ebio-in-focus%3A-stock-rises-13-2016-07-27", "https://www.nasdaq.com/articles/after-gild-earnings-which-biomed-stock-best-right-now-2016-07-26", "https://www.nasdaq.com/articles/synta-snta-cuts-q2-loss-y-y-madrigal-merger-in-focus-2016-07-22", "https://www.nasdaq.com/articles/aveo-pharmaceuticals-aveo-catches-eye%3A-stock-up-10.4-2016-07-22", "https://www.nasdaq.com/articles/bayer-bayry-beats-on-q2-earnings-updates-2016-outlook-2016-07-28", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-lgnd-jumps%3A-stock-rises-5.5-2016-07-21", "https://www.nasdaq.com/articles/bio-techne-tech-set-to-acquire-space-import-export-2016-07-06", "https://www.nasdaq.com/articles/merck-to-acquire-brazilian-animal-health-company-for-%24400m-2016-07-05", "https://www.nasdaq.com/articles/alnylam-stock-up-on-favorable-patisiran-and-revusiran-data-2016-07-05", "https://www.nasdaq.com/articles/xbiotech-xilonix-positive-in-phase-iii-colorectal-cancer-study-2016-07-04", "https://www.nasdaq.com/articles/integra-lifesciences-at-52-week-high-on-solid-q1-results-2016-07-04", "https://www.nasdaq.com/articles/arena-arna-cut-73-workforce-shifts-focus-pipeline-2016-07-01", "https://www.nasdaq.com/articles/biogen-biib-stock-q2-earnings-beat-raised-outlook-2016-07-21", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-lgnd-jumps%3A-stock-rises-5.5-2016-07-21", "https://www.nasdaq.com/articles/bio-techne-tech-set-to-acquire-space-import-export-2016-07-06", "https://www.nasdaq.com/articles/merck-to-acquire-brazilian-animal-health-company-for-%24400m-2016-07-05", "https://www.nasdaq.com/articles/two-small-cap-healthcare-stocks-are-cheap-buys-right-now-2016-06-29", "https://www.nasdaq.com/articles/esperion-espr-offers-updates-on-ldl-lowering-candidate-2016-06-29", "https://www.nasdaq.com/articles/endos-stock-gains-on-vasostricts-new-patent-approval-2016-06-29", "https://www.nasdaq.com/articles/medicines-cos-carbavance-scores-phase-iii-study-2016-06-28", "https://www.nasdaq.com/articles/bristol-myers-psioxus-strike-immuno-oncology-collaboration-2016-07-01", "https://www.nasdaq.com/articles/gw-pharmaceuticals-stock-up-on-positive-epidiolex-data-2016-06-28", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-john-bean-technologies-ani-pharmaceuticals-clearwater-paper", "https://www.nasdaq.com/articles/xbiotech-xbit-catches-eye%3A-stock-adds-5.6-in-session-2016-06-27", "https://www.nasdaq.com/articles/sanofi-inks-deal-to-swap-business-with-boehringer-ingelheim-2016-06-27", "https://www.nasdaq.com/articles/genmab-novartis-arzerra-gets-unfavorable-chmp-opinion-2016-06-24", "https://www.nasdaq.com/articles/gileads-gild-hiv-treatment-odefsey-gains-approval-in-eu-2016-06-24", "https://www.nasdaq.com/articles/5-stocks-to-buy-on-new-analyst-coverage-2016-06-24", "https://www.nasdaq.com/articles/health-care-sector-update-06282016-ttph-anip-2016-06-28", "https://www.nasdaq.com/articles/axsome-therapeutics-axsm-catches-eye%3A-stock-jumps-6.6-2016-06-24", "https://www.nasdaq.com/articles/cascadian-therapeutics-casc-jumps%3A-stock-rises-10.4-2016-06-24", "https://www.nasdaq.com/articles/retrophin-rtrx-re-024-positive-in-physician-initiated-study-2016-06-24", "https://www.nasdaq.com/articles/3-biotech-stocks-at-risk-from-the-2016-u.s.-presidential-election-anip-aria-prta-2016-06", "https://www.nasdaq.com/articles/incyte-reports-epacadostat-combination-study-initiation-2016-06-23", "https://www.nasdaq.com/articles/nymox-nymx-stock-up-on-positive-7-year-fexapotide-data-2016-06-23", "https://www.nasdaq.com/articles/epizyme-teams-up-with-roches-genentech-for-tazemetostat-2016-06-23", "https://www.nasdaq.com/articles/proteon-therapeutics-prto-in-focus%3A-stock-gains-6.4-2016-06-24", "https://www.nasdaq.com/articles/anavexs-lead-candidate-gets-orphan-drug-status-yet-again-2016-06-23", "https://www.nasdaq.com/articles/gw-pharma-gwph-to-develop-epidiolex-for-infantile-spasms-2016-06-22", "https://www.nasdaq.com/articles/redhill-rdhl-stock-up-on-positive-phase-i-data-on-yeliva-2016-06-22", "https://www.nasdaq.com/articles/prima-reports-favorable-initial-breast-cancer-study-data-2016-06-22", "https://www.nasdaq.com/articles/fates-fate-protmune-gets-fast-track-status-stock-up-2016-06-21", "https://www.nasdaq.com/articles/gilead-presents-favorable-preliminary-bictegravir-hiv-data-2016-06-21", "https://www.nasdaq.com/articles/vical-vicl-reports-phase-i-ii-data-on-genital-herpes-vaccine-2016-06-21", "https://www.nasdaq.com/articles/pluristem-therapeutics-psti-catches-eye%3A-stock-up-11.6-2016-06-23", "https://www.nasdaq.com/articles/wave-life-sciences-wve-in-focus%3A-stock-up-6.1-in-session-2016-06-21", "https://www.nasdaq.com/articles/gtx-gtxi-shows-strength%3A-stock-adds-11.2-in-session-2016-06-21", "https://www.nasdaq.com/articles/inovio-stock-up-zika-vaccine-gets-nod-for-phase-i-study-2016-06-21", "https://www.nasdaq.com/articles/auris-ears-begins-phase-iii-study-for-sudden-deafness-2016-06-20", "https://www.nasdaq.com/articles/emergent-ebs-biothrax-sbla-accepted-for-fda-review-2016-06-20", "https://www.nasdaq.com/articles/medivations-mdvn-pidilizumab-positive-in-phase-i-ii-study-2016-06-17", "https://www.nasdaq.com/articles/idera-pharmaceuticals-idra-catches-eye%3A-stock-rises-8.3-2016-06-17", "https://www.nasdaq.com/articles/sunesis-pharmaceuticals-snss-in-focus%3A-stock-gains-8.7-2016-06-21", "https://www.nasdaq.com/articles/wave-life-sciences-wve-in-focus%3A-stock-up-6.1-in-session-2016-06-21", "https://www.nasdaq.com/articles/cytokinetics-cytk-looks-good%3A-stock-adds-6.8-in-session-2016-06-16", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-offers-hal-study-data-on-jzp-110-2016-06-15", "https://www.nasdaq.com/articles/marinus-stock-down-on-dismal-phase-iii-data-on-ganaxolone-2016-06-14", "https://www.nasdaq.com/articles/abbott-labs-abt-reports-positive-data-on-freestyle-libre-2016-06-14", "https://www.nasdaq.com/articles/pfizer-reveals-final-phase-iii-data-on-inotuzumab-ozogamicin-2016-06-13", "https://www.nasdaq.com/articles/health-care-sector-update-06132016-jnj-pfe-abt-mrk-amgn-bios-anip-2016-06-13", "https://www.nasdaq.com/articles/emergent-ebs-biothrax-gets-orphan-status-in-the-u.s.-2016-06-16", "https://www.nasdaq.com/articles/dimension-therapeutics-dmtx-jumps%3A-stock-moves-6.7-up-2016-06-08", "https://www.nasdaq.com/articles/pfizers-xeljanz-positive-in-active-psoriatic-arthritis-study-2016-06-08", "https://www.nasdaq.com/articles/astrazeneca-presents-tagrisso-leptomeningeal-disease-data-2016-06-07", "https://www.nasdaq.com/articles/alexions-soliris-misses-phase-iii-primary-efficacy-endpoint-2016-06-07", "https://www.nasdaq.com/articles/exelixis-exel-shows-strength%3A-stock-moves-11.2-higher-2016-06-07", "https://www.nasdaq.com/articles/pfizer-pfe-presents-data-on-utomilumab-for-solid-tumors-2016-06-06", "https://www.nasdaq.com/articles/celldex-cldx-presents-phase-ii-melanoma-study-data-2016-06-06", "https://www.nasdaq.com/articles/nexvet-biopharma-nvet-jumps%3A-stock-moves-9.2-higher-2016-06-10", "https://www.nasdaq.com/articles/puma-pbyi-presents-favorable-phase-ii-data-on-neratinib-2016-06-06", "https://www.nasdaq.com/articles/tobira-therapeutics-tbra-in-focus%3A-stock-up-6.4-in-session-2016-06-06", "https://www.nasdaq.com/articles/merck-mrk-reveals-data-from-ongoing-studies-on-keytruda-2016-06-06", "https://www.nasdaq.com/articles/astrazeneca-sells-zurampics-eu-and-latin-american-rights-2016-06-03", "https://www.nasdaq.com/articles/amarin-amrn-looks-good%3A-stock-adds-6.7-in-session-2016-06-03", "https://www.nasdaq.com/articles/alexions-alxn-rare-disorder-drug-gets-eu-orphan-status-2016-06-02", "https://www.nasdaq.com/articles/avexis-avxs-looks-good%3A-stock-adds-6.5-in-session-2016-06-02", "https://www.nasdaq.com/articles/regeneron-sanofi-report-positive-dupilumab-phase-iii-data-2016-06-06", "https://www.nasdaq.com/articles/regeneron-reports-interim-data-on-cholesterol-lowering-drug-2016-06-01", "https://www.nasdaq.com/articles/tevas-huntington-disease-drug-receives-crl-from-the-fda-2016-06-01", "https://www.nasdaq.com/articles/ultragenyx-pharmaceutical-rare-jumps%3A-stock-up-6.6-2016-06-01", "https://www.nasdaq.com/articles/vertex-vrtx-orkambi-snda-accepted-with-priority-review-2016-06-01", "https://www.nasdaq.com/articles/integra-iart%3A-strong-revenue-growth-on-global-prospects-2016-06-01", "https://www.nasdaq.com/articles/colucid-pharmaceuticals-clcd-in-focus%3A-stock-rises-11.1-2016-06-01", "https://www.nasdaq.com/articles/biomarin-withdraws-kyndrisa-marketing-application-in-eu-2016-06-01", "https://www.nasdaq.com/articles/nektar-nktr-inks-deal-with-daiichi-sankyo-for-onzeald-2016-06-02", "https://www.nasdaq.com/articles/astrazeneca-reports-positive-phase-iii-data-on-faslodex-2016-05-31", "https://www.nasdaq.com/articles/intercepts-icpt-liver-dug-ocaliva-approved-by-the-fda-2016-05-30", "https://www.nasdaq.com/articles/will-ani-pharmaceuticals-anip-continue-to-surge-higher-2016-05-27", "https://www.nasdaq.com/articles/flexion-flxn-zilretta-gets-positive-fda-guidance-stock-up-2016-05-27", "https://www.nasdaq.com/articles/the-medicines-co.-carbavance-tango-1-study-enrolled-2016-05-27", "https://www.nasdaq.com/articles/alkermes-begins-phase-i-study-on-immuno-oncology-drug-2016-05-26", "https://www.nasdaq.com/articles/innocoll-stock-gains-on-favorable-phase-iii-data-on-xaracoll-2016-05-26", "https://www.nasdaq.com/articles/gileads-gild-new-hcv-drug-epclusa-wins-chmp-backing-2016-05-31", "https://www.nasdaq.com/articles/glaxo-innoviva-report-positive-copd-data-on-relvar-ellipta-2016-05-25", "https://www.nasdaq.com/articles/abbvie-boehringer-report-crohns-disease-drug-interim-data-2016-05-25", "https://www.nasdaq.com/articles/biodel-albireo-limited-to-combine-focus-on-liver-diseases-2016-05-25", "https://www.nasdaq.com/articles/zacks.com-featured-expert-kevin-matras-highlights%3A-ani-pharmaceuticals-kcg-holdings", "https://www.nasdaq.com/articles/should-you-get-rid-of-amag-pharmaceuticals-amag-now-2016-05-25", "https://www.nasdaq.com/articles/galapagos-ra-drug-filgotinib-to-enter-phase-iii-in-3q16-2016-05-25", "https://www.nasdaq.com/articles/alnylam-pharmaceuticals-alny-in-focus%3A-stock-rises-9.9-2016-05-26", "https://www.nasdaq.com/articles/xenoport-to-be-acquired-by-arbor-pharmaceuticals-stock-up-2016-05-24", "https://www.nasdaq.com/articles/pfizer-champixs-label-to-include-more-data-warning-lifted-2016-05-24", "https://www.nasdaq.com/articles/integra-unveils-fin-lock-glenoid-boosts-shoulder-arthroplasty-2016-05-24", "https://www.nasdaq.com/articles/value-screen-our-top-performer-year-2016-05-24", "https://www.nasdaq.com/articles/pfizers-pfe-trumenba-accepted-for-review-in-the-eu-2016-05-23", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-drna-jumps%3A-stock-rises-8.7-2016-05-23", "https://www.nasdaq.com/articles/acorda-shelves-development-epilepsy-treatment-plumiaz-2016-05-23", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-asna-anip-cvx-2016-05-25", "https://www.nasdaq.com/articles/pronai-therapeutics-dnai-shows-strength%3A-stock-rises-7.4-2016-05-20", "https://www.nasdaq.com/articles/immunogen-announces-phase-i-cohort-ovarian-cancer-data-2016-05-19", "https://www.nasdaq.com/articles/bristol-myers-reports-two-year-overall-survival-opdivo-data-2016-05-19", "https://www.nasdaq.com/articles/glaxo-innoviva-unveil-summit-study-data-on-breo-ellipta-2016-05-19", "https://www.nasdaq.com/articles/agios-strikes-metabolic-immuno-oncology-deal-with-celgene-2016-05-18", "https://www.nasdaq.com/articles/bristol-myers-opdivo-wins-fda-nod-for-additional-indication-2016-05-18", "https://www.nasdaq.com/articles/nivalis-starts-dosing-in-second-phase-ii-cystic-fibrosis-study-2016-05-17", "https://www.nasdaq.com/articles/horizon-hznp-to-buy-global-rights-to-actimmune-stock-down-2016-05-20", "https://www.nasdaq.com/articles/pfizer-pfe-reveals-positive-phase-iii-data-on-trumenba-2016-05-16", "https://www.nasdaq.com/articles/mylan-to-buy-renaissances-topical-business-for-about-%241b-2016-05-16", "https://www.nasdaq.com/articles/bayer-stops-phase-ii-adempas-study-due-to-safety-issues-2016-05-13", "https://www.nasdaq.com/articles/dr.-reddys-rdy-q4-earnings-revenues-decline-y-y-2016-05-13", "https://www.nasdaq.com/articles/zacks-investment-ideas-feature-highlights%3A-post-holding-facebook-paylocity-ani", "https://www.nasdaq.com/articles/kite-pharma-kite-upgraded-to-hold-on-strong-fundamentals-2016-05-13", "https://www.nasdaq.com/articles/perrigo-prgo-tops-q1-earnings-2016-earnings-view-intact-2016-05-12", "https://www.nasdaq.com/articles/trevena-trvn-down-on-negative-phase-iib-data-on-trv027-2016-05-17", "https://www.nasdaq.com/articles/biodelivery-collegium-collaborate-for-onsolis-in-u.s.-2016-05-12", "https://www.nasdaq.com/articles/intrexon-xon-q1-loss-wider-than-expected-revenues-miss-2016-05-11", "https://www.nasdaq.com/articles/aveo-q1-loss-in-line-with-expectation-tivozanib-in-focus-2016-05-11", "https://www.nasdaq.com/articles/synta-snta-lowers-q1-loss-y-y-focus-on-madrigal-merger-2016-05-11", "https://www.nasdaq.com/articles/puma-pbyi-reports-wider-loss-in-q1-neratinib-in-focus-2016-05-11", "https://www.nasdaq.com/articles/the-medicines-co.-loss-wider-to-divest-cardiovascular-drugs-2016-05-10", "https://www.nasdaq.com/articles/inovio-incurs-narrower-than-expected-loss-in-q1-stock-up-2016-05-10", "https://www.nasdaq.com/articles/surging-earnings-estimates-signal-good-news-for-ani-pharmaceuticals-anip-2016-05-12", "https://www.nasdaq.com/articles/arenas-arna-q1-loss-narrower-revenues-fall-short-2016-05-10", "https://www.nasdaq.com/articles/gw-pharmaceuticals-gwph-q2-loss-lower-than-expected-2016-05-06", "https://www.nasdaq.com/articles/endo-endp-lags-q1-earnings-estimates-cuts-2016-outlook-2016-05-06", "https://www.nasdaq.com/articles/agios-agio-q1-loss-lower-than-expected-pipeline-in-focus-2016-05-06", "https://www.nasdaq.com/articles/conatus-cnat-posts-in-line-q1-loss-focus-on-emricasan-2016-05-06", "https://www.nasdaq.com/articles/geron-gern-q1-loss-line-imetelstat-remains-focus-2016-05-06", "https://www.nasdaq.com/articles/celldex-cldx-posts-wider-q1-loss-focus-pipeline-2016-05-06", "https://www.nasdaq.com/articles/horizon-hznp-stock-up-despite-earnings-revenue-miss-2016-05-10", "https://www.nasdaq.com/articles/amag-amag-q1-earnings-beat-estimates-keeps-2016-view-2016-05-04", "https://www.nasdaq.com/articles/zoetis-zts-tops-q1-earnings-revenues-updates-outlook-2016-05-04", "https://www.nasdaq.com/articles/illumina-ilmn-misses-on-q1-earnings-lowers-16-guidance-2016-05-04", "https://www.nasdaq.com/articles/vivus-vvus-q1-loss-narrower-qsymia-sales-decline-2016-05-04", "https://www.nasdaq.com/articles/mylan-beats-on-q1-earnings-revenues-lag-2016-view-intact-2016-05-03", "https://www.nasdaq.com/articles/surmodics-srdx-beats-q2-earnings-revenues-estimates-2016-05-03", "https://www.nasdaq.com/articles/novo-nordisk-nvo-beats-on-q1-earnings-retains-outlook-2016-05-02", "https://www.nasdaq.com/articles/regeneron-regn-tops-q1-earnings-ups-2016-eylea-view-2016-05-05", "https://www.nasdaq.com/articles/integra-iart-beats-on-q1-earnings-grows-organically-2016-04-28", "https://www.nasdaq.com/articles/new-strong-buy-stocks-for-april-26th-2016-04-26", "https://www.nasdaq.com/articles/health-care-sector-update-04052016-icpt-anip-2016-04-05", "https://www.nasdaq.com/articles/health-care-sector-update-01052016-anip-galt-immu-2016-01-05", "https://www.nasdaq.com/articles/health-care-sector-update-12292015-uso-ung-erb-2015-12-29", "https://www.nasdaq.com/articles/3-great-biotech-stocks-you-havent-heard-2015-12-19", "https://www.nasdaq.com/articles/ani-pharmaceuticals-anip%3A-an-off-the-radar-potential-winner-2015-11-30", "https://www.nasdaq.com/articles/cambrex-cbm-catches-eye%3A-stock-adds-8.5-in-session-2016-05-02", "https://www.nasdaq.com/articles/ani-pharmaceuticals-anip-in-focus%3A-stock-surges-10.5-2015-10-06", "https://www.nasdaq.com/articles/5-sell-ranked-biotechs-fell-more-5-today-2015-09-25", "https://www.nasdaq.com/articles/ani-pharmaceuticals-anip-falls%3A-stock-goes-down-15.8-2015-09-23", "https://www.nasdaq.com/articles/company-news-for-september-22-2015-2015-09-22", "https://www.nasdaq.com/articles/ani-pharmaceuticals-inks-deal-with-merck-for-2-ndas-2015-09-22", "https://www.nasdaq.com/articles/should-you-get-rid-of-ani-pharmaceuticals-anip-now-2015-08-12", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-august-6th-tale-of-the-tape-2015-08-07", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-october-13th-2015-10-13", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-july-2nd-tale-of-the-tape-2015-07-02", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-june-29th-tale-of-the-tape-2015-06-29", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-june-18th-tale-of-the-tape-2015-06-18", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-june-9th-tale-of-the-tape-2015-06-09", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-june-4th-tale-of-the-tape-2015-06-04", "https://www.nasdaq.com/articles/undervalued-stocks-biotech-worth-buying-2015-05-28", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-may-22nd-tale-of-the-tape-2015-05-22", "https://www.nasdaq.com/articles/health-care-sector-update-07132015-nvls-cltx-anip-2015-07-13", "https://www.nasdaq.com/articles/3-comeback-stocks-buy-healthcare-2015-05-12", "https://www.nasdaq.com/articles/10-most-profitable-companies-healthcare-2015-05-07", "https://www.nasdaq.com/articles/oncomed-down-on-phase-ib-lung-cancer-study-data-analyst-blog-2015-04-20", "https://www.nasdaq.com/articles/oncolytics-reolysin-gets-one-more-orphan-drug-status-analyst-blog-2015-04-20", "https://www.nasdaq.com/articles/trovagenes-trov-pcm-data-impresses-shares-rally-analyst-blog-2015-04-20", "https://www.nasdaq.com/articles/receptos-gains-on-positive-phase-ii-data-on-ozanimod-analyst-blog-2015-04-17", "https://www.nasdaq.com/articles/actelion-to-boost-progress-of-specialty-immunology-pipeline-analyst-blog-2015-04-16", "https://www.nasdaq.com/articles/why-ani-pharmaceuticals-anip-could-be-positioned-for-a-slump-tale-of-the-tape-2015-05-13", "https://www.nasdaq.com/articles/glaxo-downgraded-to-strong-sell-delete-from-your-portfolio-analyst-blog-2015-04-16", "https://www.nasdaq.com/articles/gw-pharmaceuticals-up-to-strong-buy-on-strong-pipeline-analyst-blog-2015-04-16", "https://www.nasdaq.com/articles/arca-biopharma-gains-on-fast-track-status-for-gencaro-analyst-blog-2015-04-14", "https://www.nasdaq.com/articles/aeterna-zentaris-to-advance-hormone-drug-to-phase-iii-study-analyst-blog-2015-04-14", "https://www.nasdaq.com/articles/adamas-pharmas-lead-candidate-gets-orphan-status-in-u.s.-analyst-blog-2015-04-13", "https://www.nasdaq.com/articles/horizon-pharmas-actimmune-gets-fast-track-status-analyst-blog-2015-04-13", "https://www.nasdaq.com/articles/health-care-sector-update-04102015-arna-vrtx-anip-2015-04-10", "https://www.nasdaq.com/articles/the-medicines-co.s-kengreal-backed-for-fda-approval-analyst-blog-2015-04-16", "https://www.nasdaq.com/articles/clovis-oncologys-rucaparib-gets-breakthrough-status-analyst-blog-2015-04-07", "https://www.nasdaq.com/articles/sage-therapeutics-lead-candidate-to-enter-phase-iii-study-analyst-blog-2015-04-06", "https://www.nasdaq.com/articles/can-qiagen-continue-to-grow-in-molecular-diagnostics-space-analyst-blog-2015-04-01", "https://www.nasdaq.com/articles/heat-biologics-posts-wider-loss-y-y-focus-on-pipeline-analyst-blog-2015-03-30", "https://www.nasdaq.com/articles/novo-nordisk-to-submit-interim-devote-data-to-the-fda-analyst-blog-2015-03-27", "https://www.nasdaq.com/articles/novo-nordisks-onset-1-onset-2-meet-primary-objectives-analyst-blog-2015-03-26", "https://www.nasdaq.com/articles/regenerons-eylea-gets-fda-approval-for-label-expansion-analyst-blog-2015-03-26", "https://www.nasdaq.com/articles/novo-nordisks-tresiba-ryzodeg-ndas-under-fda-review-analyst-blog-2015-04-09", "https://www.nasdaq.com/articles/isis-pharmaceuticals-reports-phase-i-data-on-lipid-candidate-analyst-blog-2015-03-24", "https://www.nasdaq.com/articles/myriad-poised-on-portfolio-strength-despite-y-y-downfall-in-q2-analyst-blog-2015-03-23", "https://www.nasdaq.com/articles/eli-lilly-partners-with-innovent-to-develop-oncology-drugs-analyst-blog-2015-03-23", "https://www.nasdaq.com/articles/pfizer-reveals-detailed-xeljanz-data-from-psoriasis-study-analyst-blog-2015-03-23", "https://www.nasdaq.com/articles/prothenas-prx002-positive-in-parkinsons-disease-study-analyst-blog-2015-03-20", "https://www.nasdaq.com/articles/amicus-to-seek-for-migalastats-approval-in-the-u.s.-eu-analyst-blog-2015-03-20", "https://www.nasdaq.com/articles/eli-lilly-collaborates-with-korean-hanmi-pharmaceutical-analyst-blog-2015-03-20", "https://www.nasdaq.com/articles/lpath-lptn-crumbles-on-failure-of-kidney-cancer-drug-trial-analyst-blog-2015-03-25", "https://www.nasdaq.com/articles/genomic-health-prostrate-cancer-test-grows-but-hits-margins-analyst-blog-2015-03-18", "https://www.nasdaq.com/articles/kite-pharma-kite-acquires-t-cell-factory-focus-on-europe-analyst-blog-2015-03-18", "https://www.nasdaq.com/articles/epizyme-epzm-crumbles%3A-stock-falls-by-9.6-tale-of-the-tape-2015-03-16", "https://www.nasdaq.com/articles/actelions-uptravi-shows-long-term-benefit-in-griphon-analyst-blog-2015-03-16", "https://www.nasdaq.com/articles/epizymes-loss-narrower-than-expected-focus-on-pipeline-analyst-blog-2015-03-13", "https://www.nasdaq.com/articles/syntas-q4-loss-narrows-y-y-focus-on-lung-cancer-drug-analyst-blog-2015-03-13", "https://www.nasdaq.com/articles/trovagene-trov-posts-wider-q4-loss-on-higher-expenses-analyst-blog-2015-03-13", "https://www.nasdaq.com/articles/lexicon-ipsen-agreement-expanded-to-include-canada-analyst-blog-2015-03-19", "https://www.nasdaq.com/articles/affymetrix-hits-52-week-high-on-stellar-q4-positive-outlook-analyst-blog-2015-03-13", "https://www.nasdaq.com/articles/regado-biosciences-rgdo-jumps%3A-stock-surges-20.3-tale-of-the-tape-2015-03-09", "https://www.nasdaq.com/articles/myriad-genetics-unveils-simoa-based-immunoassay-services-analyst-blog-2015-03-09", "https://www.nasdaq.com/articles/bristol-myers-oncology-drug-opdivo-label-expanded-in-u.s.-analyst-blog-2015-03-06", "https://www.nasdaq.com/articles/fibrocell-science-fcsc-in-focus%3A-stock-surges-11-tale-of-the-tape-2015-03-04", "https://www.nasdaq.com/articles/is-illumina-ilmn-worth-adding-to-your-portfolio-now-analyst-blog-2015-03-03", "https://www.nasdaq.com/articles/amgen-celimmune-tie-up-for-autoimmune-disorder-drug-analyst-blog-2015-03-03", "https://www.nasdaq.com/articles/is-illumina-ilmn-worth-adding-to-your-portfolio-now-analyst-blog-2015-03-13", "https://www.nasdaq.com/articles/keryx-biopharmaceuticals-q4-loss-wider-than-expected-analyst-blog-2015-03-02", "https://www.nasdaq.com/articles/roches-avastin-gets-positive-opinion-for-cervical-cancer-analyst-blog-2015-03-02", "https://www.nasdaq.com/articles/gileads-gild-hiv-drug-positive-in-2-phase-iii-studies-analyst-blog-2015-03-02", "https://www.nasdaq.com/articles/alexions-soliris-label-may-be-updated-upon-ec-approval-analyst-blog-2015-03-02", "https://www.nasdaq.com/articles/amgens-kyprolis-under-eu-review-analyst-blog-2015-02-28", "https://www.nasdaq.com/articles/aegerions-q4-loss-narrows-y-y-ups-juxtapid-sales-view-analyst-blog-2015-02-27", "https://www.nasdaq.com/articles/merge-healthcare-mrge-q4-earnings-up-y-y-revenues-miss-analyst-blog-2015-02-26", "https://www.nasdaq.com/articles/bristol-myers-files-for-new-indications-for-yervoy-opdivo-analyst-blog-2015-03-03", "https://www.nasdaq.com/articles/illumina-expands-ngs-portfolio-with-neoprep-library-system-analyst-blog-2015-02-24", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-friday-tale-of-the-tape-2015-02-20", "https://www.nasdaq.com/articles/spdr-sp-pharmaceuticals-etf-insider-buying-index-registering-101-2014-12-30", "https://www.nasdaq.com/articles/amag-takeda-mutually-end-agreement-for-feraheme-analyst-blog-2014-12-30", "https://www.nasdaq.com/articles/biomarins-vimizim-okd-in-japan-for-morquio-a-syndrome-analyst-blog-2014-12-30", "https://www.nasdaq.com/articles/actelion-submits-new-drug-application-for-uptravi-in-the-u.s.-analyst-blog-2014-12-23", "https://www.nasdaq.com/articles/stryker-osiris-team-up-to-market-viable-bone-matrix-analyst-blog-2014-12-23", "https://www.nasdaq.com/articles/integra-lifesciences-tops-q4-earnings-revenues-up-y-y-analyst-blog-2015-02-25", "https://www.nasdaq.com/articles/illumina-expands-ngs-portfolio-with-neoprep-library-system-analyst-blog-2015-02-24", "https://www.nasdaq.com/articles/integra-lifesciences-up-on-launch-of-bilayer-skin-product-analyst-blog-2014-12-19", "https://www.nasdaq.com/articles/bruker-unveils-bioafm-system-for-high-resolution-imaging-analyst-blog-2014-12-18", "https://www.nasdaq.com/articles/ovascience-slumps%3A-ovas-tanks-12.3-in-session-tale-of-the-tape-2014-12-16", "https://www.nasdaq.com/articles/biodelivery-sciences-bdsi-in-focus%3A-stock-tanks-11-tale-of-the-tape-2014-12-16", "https://www.nasdaq.com/articles/alkermes-starts-phase-i-study-on-schizophrenia-candidate-analyst-blog-2014-12-16", "https://www.nasdaq.com/articles/acordas-ampyra-in-phase-iii-for-post-stroke-walking-deficit-analyst-blog-2014-12-16", "https://www.nasdaq.com/articles/will-myrisk-cancer-test-work-wonders-for-myriad-genetics-analyst-blog-2014-12-23", "https://www.nasdaq.com/articles/one-stock-chart-trick-you-should-all-know-investment-ideas-2014-12-16", "https://www.nasdaq.com/articles/strength-seen-in-gtx-inc-gtxi%3A-stock-rises-10.6-tale-of-the-tape-2014-12-15", "https://www.nasdaq.com/articles/alder-biopharmaceuticals-slumps%3A-aldr-falls-5.5-in-session-tale-of-the-tape-2014-12-15", "https://www.nasdaq.com/articles/alexions-soliris-receives-orphan-drug-status-in-japan-analyst-blog-2014-12-15", "https://www.nasdaq.com/articles/sangamo-biosciences-sgmo-jumps%3A-stock-rises-7.2-tale-of-the-tape-2014-12-12", "https://www.nasdaq.com/articles/alder-biopharmaceuticals-inc.-aldr-in-focus%3A-stock-soars-31.9-tale-of-the-tape-2014-12-12", "https://www.nasdaq.com/articles/celladon-corporation-cldn-falls%3A-stock-goes-down-8.6-tale-of-the-tape-2014-12-12", "https://www.nasdaq.com/articles/genomic-healths-breast-cancer-test-yields-positive-results-analyst-blog-2014-12-16", "https://www.nasdaq.com/articles/genomic-healths-liquid-biopsy-tests-positive-in-twin-studies-analyst-blog-2014-12-11", "https://www.nasdaq.com/articles/kite-pharma-kite-shows-strength%3A-stock-moves-up-16.4-tale-of-the-tape-2014-12-10", "https://www.nasdaq.com/articles/avalanche-biotechnologies-aavl-jumps%3A-stock-adds-6.1-in-session-tale-of-the-tape-2014-12", "https://www.nasdaq.com/articles/celladon-corp.-cldn-jumps%3A-stock-adds-14.7-in-session-tale-of-the-tape-2014-12-10", "https://www.nasdaq.com/articles/myriad-genetics-unveils-positive-cancer-study-results-analyst-blog-2014-12-10", "https://www.nasdaq.com/articles/rexahn-pharmaceuticals-inc.-rnn-rises%3A-stock-up-8.6-tale-of-the-tape-2014-12-09", "https://www.nasdaq.com/articles/acceleron-pharma-inc.-xlrn-in-focus%3A-stock-soars-13.6-tale-of-the-tape-2014-12-09", "https://www.nasdaq.com/articles/ophthotech-corporation-opht-jumps%3A-stock-gains-5-tale-of-the-tape-2014-12-11", "https://www.nasdaq.com/articles/genomic-healths-liquid-biopsy-tests-positive-in-twin-studies-analyst-blog-2014-12-11", "https://www.nasdaq.com/articles/kite-pharma-kite-shows-strength%3A-stock-moves-up-16.4-tale-of-the-tape-2014-12-10", "https://www.nasdaq.com/articles/array-biopharma-inc.-arry-in-focus%3A-stock-soars-14.3-tale-of-the-tape-2014-12-05", "https://www.nasdaq.com/articles/is-ani-pharmaceuticals-anip-stock-a-solid-choice-right-now-tale-of-the-tape-2014-12-05", "https://www.nasdaq.com/articles/walgreens-wag-up-on-4.9-y-y-rise-in-november-sales-analyst-blog-2014-12-05", "https://www.nasdaq.com/articles/celldexs-glembatumumab-vedotin-in-phase-ii-for-melanoma-analyst-blog-2014-12-05", "https://www.nasdaq.com/articles/cara-therapeutics-cara-in-focus%3A-stock-rises-6.1-tale-of-the-tape-2014-12-08", "https://www.nasdaq.com/articles/sequenom-inc.-sqnm-in-focus%3A-stock-surges-23.6-tale-of-the-tape-2014-12-04", "https://www.nasdaq.com/articles/adma-biologics-ri-002-positive-in-phase-iii-study-analyst-blog-2014-12-04", "https://www.nasdaq.com/articles/health-care-sector-update-12042014-anipkinappy-2014-12-04", "https://www.nasdaq.com/articles/genomic-healths-oncotype-dx%3A-cancer-testing-made-easier-analyst-blog-2014-12-04", "https://www.nasdaq.com/articles/biogen-idec-biib-shows-strength%3A-stock-moves-6.4-up-tale-of-the-tape-2014-12-03", "https://www.nasdaq.com/articles/merge-healthcare-nextgen-to-expand-interoperability-solution-analyst-blog-2014-12-03", "https://www.nasdaq.com/articles/myriad-genetics-prolaris%3A-a-pocket-friendly-cancer-test-analyst-blog-2014-12-03", "https://www.nasdaq.com/articles/merge-healthcare-mrge-worth-watching%3A-stock-gains-6.5-tale-of-the-tape-2014-12-04", "https://www.nasdaq.com/articles/coronado-biosciences-inc.-cndo-in-focus%3A-stock-soars-17.6-tale-of-the-tape-2014-11-28", "https://www.nasdaq.com/articles/merge-healthcare-primordial-to-improve-radiology-solutions-analyst-blog-2014-11-28", "https://www.nasdaq.com/articles/what-makes-biodelivery-sciences-bdsi-a-strong-sell-tale-of-the-tape-2014-11-26", "https://www.nasdaq.com/articles/isis-pharmaceuticals-earns-milestone-on-study-initiation-analyst-blog-2014-11-26", "https://www.nasdaq.com/articles/five-prime-therapeutics-inc.-fprx-in-focus%3A-stock-soars-31.4-tale-of-the-tape-2014-11-25", "https://www.nasdaq.com/articles/coronado-biosciences-cndo-jumps%3A-stock-rises-8.5-tale-of-the-tape-2014-11-25", "https://www.nasdaq.com/articles/epirus-biopharmaceuticals-eprs-jumps%3A-stock-up-15.9-tale-of-the-tape-2014-11-21", "https://www.nasdaq.com/articles/uniqure-n.v.-qure-in-focus%3A-stock-soars-17.6-tale-of-the-tape-2014-11-28", "https://www.nasdaq.com/articles/novavax-gains-on-fast-track-designation-for-rsv-f-vaccine-analyst-blog-2014-11-21", "https://www.nasdaq.com/articles/trovagene-cancer-technology-detects-kras-mutation-analyst-blog-2014-11-21", "https://www.nasdaq.com/articles/myriad-genetics-tesaro-tie-up-for-mychoice-cancer-test-analyst-blog-2014-11-21", "https://www.nasdaq.com/articles/myriads-vectra-da%3A-a-better-indicator-for-rheumatoid-arthritis-analyst-blog-2014-11-20", "https://www.nasdaq.com/articles/amarin-corporation-plc-amrn-in-focus%3A-stock-soars-23.4-tale-of-the-tape-2014-11-19", "https://www.nasdaq.com/articles/omnicell-offers-advanced-ot-automation-at-hospital-in-riyadh-analyst-blog-2014-11-19", "https://www.nasdaq.com/articles/illumina-biomerieux-to-co-develop-ngs-epidemiology-solution-analyst-blog-2014-11-19", "https://www.nasdaq.com/articles/compugen-cgen-worth-watching%3A-stock-adds-6-in-session-tale-of-the-tape-2014-11-21", "https://www.nasdaq.com/articles/celldex-therapeutics-inc-cldx-focus-stock-soars-289-tale-tape-2014-11-18", "https://www.nasdaq.com/articles/kite-pharma-gains-on-positive-opinion-for-kte-c19-analyst-blog-2014-11-18", "https://www.nasdaq.com/articles/kite-pharmas-q3-loss-narrows-y-y-focus-on-pipeline-analyst-blog-2014-11-17", "https://www.nasdaq.com/articles/puma-biotechnology-slumps%3A-pbyi-tumbles-9.7-in-session-tale-of-the-tape-2014-11-17", "https://www.nasdaq.com/articles/integra-iart-strengthens-spinal-implant-with-twin-launches-analyst-blog-2014-11-17", "https://www.nasdaq.com/articles/affymetrix-affx-now-a-strong-buy-raised-guidance-positive-analyst-blog-2014-11-14", "https://www.nasdaq.com/articles/intercept-pharmaceuticals-slumps%3A-icpt-falls-5.9-in-session-tale-of-the-tape-2014-11-13", "https://www.nasdaq.com/articles/amicus-therapeutics-inc.-fold-in-focus%3A-stock-soars-17.8-tale-of-the-tape-2014-11-18", "https://www.nasdaq.com/articles/ani-pharma-anip-sucampo-pharma-scmp-top-momentum-stocks-add-your-portfolio-video-blog-2014", "https://www.nasdaq.com/articles/why-ani-pharmaceuticals-anip-could-be-positioned-for-a-surge-tale-of-the-tape-2014-11-07", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-thursday-tale-of-the-tape-2014-11-06", "https://www.nasdaq.com/articles/celldex-falls-with-pipeline-update-overshadowing-q3-results-analyst-blog-2014-11-06", "https://www.nasdaq.com/articles/insider-bets-paying-anip-new-52-week-high-reached-2014-11-03", "https://www.nasdaq.com/articles/3-money-making-biotech-stocks-could-go-higher-2014-10-24", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-monday-tale-of-the-tape-2014-10-06", "https://www.nasdaq.com/articles/can-the-rally-in-ani-pharmaceuticals-anip-shares-continue-tale-of-the-tape-2014-11-13", "https://www.nasdaq.com/articles/ani-pharmaceuticals-anip-in-focus%3A-stock-surges-11-tale-of-the-tape-2014-08-05", "https://www.nasdaq.com/articles/sector-update-health-care-2014-08-04-1", "https://www.nasdaq.com/articles/sector-update-health-care-stocks-underwater-group-ani-pharma-jumps-after-narrowing-q2-net", "https://www.nasdaq.com/articles/walgreens-sees-robust-growth-in-june-sales-analyst-blog-2014-07-08", "https://www.nasdaq.com/articles/ucb-dermira-sign-cimzia-dermatology-deal-analyst-blog-2014-07-07", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-to-buy-rights-to-defibrotide-shares-up-analyst-blog-2014-07-03", "https://www.nasdaq.com/articles/sanofi-and-curevac-ink-vaccine-deal-analyst-blog-2014-07-03", "https://www.nasdaq.com/articles/zacks-rank-5-additions-for-tuesday-tale-of-the-tape-2014-09-02", "https://www.nasdaq.com/articles/edwards-lifesciences-monitor-gets-fda-nod-analyst-blog-2014-07-02", "https://www.nasdaq.com/articles/geron-corp.-gern-jumps%3A-stock-moves-8.1-higher-tale-of-the-tape-2014-07-01", "https://www.nasdaq.com/articles/dicerna-pharmaceuticals-drna-soars%3A-stock-rises-19.8-tale-of-the-tape-2014-07-01", "https://www.nasdaq.com/articles/aveo-pharmaceuticals-aveo-jumps%3A-stock-rises-6.4-tale-of-the-tape-2014-07-01", "https://www.nasdaq.com/articles/curis-cris-soars%3A-stock-adds-11.4-in-session-tale-of-the-tape-2014-07-01", "https://www.nasdaq.com/articles/illumina-expands-in-europe-on-3-nipt-deals-analyst-blog-2014-07-01", "https://www.nasdaq.com/articles/ucbs-vimpat-positive-for-partial-onset-seizures-analyst-blog-2014-06-30", "https://www.nasdaq.com/articles/strength-seen-in-amicus-therapeutics-inc.-fold-as-stock-rallies-19.46-tale-of-the-tape", "https://www.nasdaq.com/articles/dyax-corp.-dyax-soars%3A-stock-rises-12.5-tale-of-the-tape-2014-06-30", "https://www.nasdaq.com/articles/discovery-laboratories-inc.-dsco-in-focus%3A-stock-rises-7.83-tale-of-the-tape-2014-06-30", "https://www.nasdaq.com/articles/integra-lifesciences-down-to-sell-analyst-blog-2014-06-30", "https://www.nasdaq.com/articles/paciras-exparel-positive-in-phase-iv-studies-analyst-blog-2014-06-27", "https://www.nasdaq.com/articles/brukers-maldi-biotyper-approved-for-biochemical-testing-in-china-analyst-blog-2014-06-27", "https://www.nasdaq.com/articles/prothena-corporation-prta-falls%3A-stock-goes-down-5.3-tale-of-the-tape-2014-06-26", "https://www.nasdaq.com/articles/glaxos-promacta-in-phase-iii-for-mds-analyst-blog-2014-06-26", "https://www.nasdaq.com/articles/bind-therapeutics-bind-soars%3A-stock-adds-9.1-in-session-tale-of-the-tape-2014-06-30", "https://www.nasdaq.com/articles/nanosphere-nsph-jumps%3A-stock-rises-14.6-tale-of-the-tape-2014-06-24", "https://www.nasdaq.com/articles/alkermes-plc-alks-jumps%3A-stock-rises-5.7-tale-of-the-tape-2014-06-23", "https://www.nasdaq.com/articles/strength-seen-in-cara-therapeutics-inc.-cara-as-stock-rallies-19.60-tale-of-the-tape-2014", "https://www.nasdaq.com/articles/ultragenyx-pharmaceutical-rare-jumps%3A-stock-up-6.5-tale-of-the-tape-2014-06-19", "https://www.nasdaq.com/articles/insmed-incorporated-insm-catches-eye%3A-stock-surges-42.6-tale-of-the-tape-2014-06-19", "https://www.nasdaq.com/articles/protalix-plx-in-focus%3A-stock-adds-6.5-in-session-tale-of-the-tape-2014-06-19", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-in-focus%3A-stock-moves-7.8-higher-tale-of-the-tape-2014-06-19", "https://www.nasdaq.com/articles/strength-seen-in-vertex-pharmaceuticals-incorporated-vrtx-as-stock-shoots-40.41-tale-of", "https://www.nasdaq.com/articles/intra-cellular-therapies-inc.-itci-in-focus%3A-stock-rises-8.74-tale-of-the-tape-2014-06-19", "https://www.nasdaq.com/articles/aveo-pharmaceuticals-aveo-catches-eye%3A-stock-up-11.4-tale-of-the-tape-2014-06-18", "https://www.nasdaq.com/articles/orexigen-orex-in-focus%3A-stock-moves-7.5-higher-tale-of-the-tape-2014-06-17", "https://www.nasdaq.com/articles/sequenom-inc.-sqnm-soars%3A-stock-rises-9.2-tale-of-the-tape-2014-06-17", "https://www.nasdaq.com/articles/achillion-pharmaceuticals-achn-jumps%3A-stock-up-20.9-tale-of-the-tape-2014-06-17", "https://www.nasdaq.com/articles/strength-seen-in-bluebird-bio-inc.-blue-as-stock-shoots-up-32.08-tale-of-the-tape-2014-06", "https://www.nasdaq.com/articles/what-falling-estimates-price-mean-for-rexahn-pharmaceuticals-rnn-tale-of-the-tape-2014-06", "https://www.nasdaq.com/articles/applied-genetic-technologies-agtc-jumps%3A-stock-up-6.1-tale-of-the-tape-2014-06-19", "https://www.nasdaq.com/articles/integra-lifesciences-premier-ink-3-year-purchase-deal-analyst-blog-2014-06-16", "https://www.nasdaq.com/articles/will-forest-labs-retain-namenda-market-share-analyst-blog-2014-06-13", "https://www.nasdaq.com/articles/bind-therapeutics-bind-soars%3A-stock-up-6.8-tale-of-the-tape-2014-06-13", "https://www.nasdaq.com/articles/sunesis-pharmaceuticals-snss-soars%3A-stock-adds-8-in-session-tale-of-the-tape-2014-06-13", "https://www.nasdaq.com/articles/progenics-pharmaceuticals-inc.-pgnx-in-focus%3A-stock-rises-9.23-tale-of-the-tape-2014-06-13", "https://www.nasdaq.com/articles/avanir-gains-avp-825-hits-phase-iii-primary-endpoint-analyst-blog-2014-06-12", "https://www.nasdaq.com/articles/auxilium-pharma-launches-authorized-generic-testim-analyst-blog-2014-06-12", "https://www.nasdaq.com/articles/actelions-selexipag-meets-primary-endpoint-analyst-blog-2014-06-16", "https://www.nasdaq.com/articles/vital-therapies-vtl-catches-eye%3A-stock-surges-20.7-tale-of-the-tape-2014-06-12", "https://www.nasdaq.com/articles/orexigen-therapeutics-orex-in-focus%3A-stock-tumbles-14.7-tale-of-the-tape-2014-06-12", "https://www.nasdaq.com/articles/biodelivery-sciences-international-bdsi-jumps%3A-stock-up-14.1-tale-of-the-tape-2014-06-12", "https://www.nasdaq.com/articles/achillion-pharmaceuticals-achn-in-focus%3A-stock-falls-6.4-tale-of-the-tape-2014-06-12", "https://www.nasdaq.com/articles/ocera-therapeutics-ocrx-soars%3A-stock-adds-11.8-in-session-tale-of-the-tape-2014-06-12", "https://www.nasdaq.com/articles/genomic-healths-oncotype-dx-redefines-breast-cancer-therapy-analyst-blog-2014-06-12", "https://www.nasdaq.com/articles/merck-kgaa-morphosys-sign-deal-immuno-oncology-in-focus-analyst-blog-2014-06-12", "https://www.nasdaq.com/articles/geron-corp.-gern-soars%3A-stock-up-10.6-tale-of-the-tape-2014-06-12", "https://www.nasdaq.com/articles/merck-kgaa-auxogyns-eeva-system-gets-fda-clearance-analyst-blog-2014-06-11", "https://www.nasdaq.com/articles/isis-pharma-earns-milestone-payment-on-study-initiation-analyst-blog-2014-06-10", "https://www.nasdaq.com/articles/strength-seen-in-inovio-ino%3A-stock-rises-9.4-tale-of-the-tape-2014-06-10", "https://www.nasdaq.com/articles/achillion-pharmaceuticals-achn-in-focus%3A-stock-rises-47.6-tale-of-the-tape-2014-06-10", "https://www.nasdaq.com/articles/why-puma-biotechnology-pbyi-could-be-positioned-for-a-slump-tale-of-the-tape-2014-06-10", "https://www.nasdaq.com/articles/idenix-pharmaceuticals-idix-soars%3A-stock-rises-229.1-tale-of-the-tape-2014-06-10", "https://www.nasdaq.com/articles/aveo-pharmaceuticals-inc.-aveo-in-focus%3A-stock-rises-7.8-tale-of-the-tape-2014-06-10", "https://www.nasdaq.com/articles/oragenics-ogen-in-focus%3A-stock-adds-6-in-session-tale-of-the-tape-2014-06-11", "https://www.nasdaq.com/articles/fibrocell-science-fcsc-in-focus%3A-stock-rises-14.4-tale-of-the-tape-2014-06-09", "https://www.nasdaq.com/articles/novavax-nvax-crumbles%3A-stock-tumbles-by-7.7-tale-of-the-tape-2014-06-09", "https://www.nasdaq.com/articles/biodelivery-sciences-bunavail-gets-fda-nod-analyst-blog-2014-06-09", "https://www.nasdaq.com/articles/celldex-therapeutics-cldx-soars%3A-stock-adds-12.6-in-session-tale-of-the-tape-2014-06-06", "https://www.nasdaq.com/articles/clovis-oncology-clvs-jumps%3A-stock-rises-6.2-tale-of-the-tape-2014-06-06", "https://www.nasdaq.com/articles/affymetrix-biodiscovery-launch-cancer-research-software-analyst-blog-2014-06-06", "https://www.nasdaq.com/articles/mannkind-corp.-mnkd-soars%3A-stock-adds-10.8-in-session-tale-of-the-tape-2014-06-05", "https://www.nasdaq.com/articles/integra-lifesciences-down-to-sell-on-poor-q1-segment-show-analyst-blog-2014-06-10", "https://www.nasdaq.com/articles/acadia-healthcare-company-achc-cqh-soars%3A-stock-adds-14.1-in-session-tale-of-the-tape-2014", "https://www.nasdaq.com/articles/applied-genetic-agtc-soars%3A-stock-up-44.1-tale-of-the-tape-2014-06-03", "https://www.nasdaq.com/articles/eli-lillys-cyramza-revels-in-phase-iii-analyst-blog-2014-06-03", "https://www.nasdaq.com/articles/myriad-genetics-posts-key-mypath-melanoma-data-analyst-blog-2014-06-03", "https://www.nasdaq.com/articles/allergan-inc.-agn-in-focus%3A-stock-rises-5.65-tale-of-the-tape-2014-06-02", "https://www.nasdaq.com/articles/sanofis-lemtrada-accepted-for-fda-review-analyst-blog-2014-06-02", "https://www.nasdaq.com/articles/amicus-therapeutics-fold-soars%3A-stock-up-10-tale-of-the-tape-2014-05-30", "https://www.nasdaq.com/articles/halozyme-study-clinical-hold-lifted-by-fda-analyst-blog-2014-06-05", "https://www.nasdaq.com/articles/genomic-health-posts-fresh-oncotype-dx-data-analyst-blog-2014-05-30", "https://www.nasdaq.com/articles/xenoport-inc.-xnpt-soars%3A-stock-up-5.9-tale-of-the-tape-2014-05-29", "https://www.nasdaq.com/articles/gtx-inc.-gtxi-soars%3A-stock-up-9.7-tale-of-the-tape-2014-05-29", "https://www.nasdaq.com/articles/verastem-vstm-in-focus%3A-stock-adds-14-in-session-tale-of-the-tape-2014-05-28", "https://www.nasdaq.com/articles/isis-pharmaceuticals-inc.-isis-in-focus%3A-stock-rises-9.21-tale-of-the-tape-2014-05-28", "https://www.nasdaq.com/articles/strength-seen-in-ptc-therapeutics-inc.-ptct-as-stock-shoots-up-30.74-tale-of-the-tape-2014", "https://www.nasdaq.com/articles/medtronic-unveils-new-corevalve-data-analyst-blog-2014-05-22", "https://www.nasdaq.com/articles/arqule-inc.-arql-in-focus%3A-stock-rises-8.21-tale-of-the-tape-2014-05-30", "https://www.nasdaq.com/articles/why-ani-pharmaceuticals-anip-could-shock-the-market-soon-tale-of-the-tape-2014-05-21", "https://www.nasdaq.com/articles/auspex-pharmaceuticals-aspx-jumps%3A-stock-rises-9.5-tale-of-the-tape-2014-05-21", "https://www.nasdaq.com/articles/myriad-genetics-unveils-positive-prolaris-data-analyst-blog-2014-05-21", "https://www.nasdaq.com/articles/genomic-health%3A-study-boosts-oncotype-dx-again-analyst-blog-2014-05-21", "https://www.nasdaq.com/articles/carefusion-hits-new-52-week-high-analyst-blog-2014-05-20", "https://www.nasdaq.com/articles/genomic-health-presents-new-oncotype-dx-data-analyst-blog-2014-05-19", "https://www.nasdaq.com/articles/xenoport-reckitt-benckiser-pharma-collaborate-analyst-blog-2014-05-16", "https://www.nasdaq.com/articles/insmed-insm-in-focus%3A-stock-moves-6.7-higher-tale-of-the-tape-2014-05-21", "https://www.nasdaq.com/articles/progenics-q1-loss-narrows-analyst-blog-2014-05-15", "https://www.nasdaq.com/articles/myriad-genetics-arm-offers-new-vectra-da-data-analyst-blog-2014-05-15", "https://www.nasdaq.com/articles/adcare-health-systems-adk-in-focus%3A-stock-moves-5.1-higher-tale-of-the-tape-2014-05-14", "https://www.nasdaq.com/articles/halozyme-therapeutics-inc.-halo-in-focus%3A-stock-up-6.9-tale-of-the-tape-2014-05-14", "https://www.nasdaq.com/articles/pipeline-update-from-biodelivery-sciences-analyst-blog-2014-05-14", "https://www.nasdaq.com/articles/xenoports-q1-loss-narrows-analyst-blog-2014-05-14", "https://www.nasdaq.com/articles/halozymes-q1-loss-widens-analyst-blog-2014-05-13", "https://www.nasdaq.com/articles/clovis-oncology-inc.-clvs-in-focus%3A-stock-surges-16-tale-of-the-tape-2014-05-16", "https://www.nasdaq.com/articles/radnet-rdnt-surges%3A-stock-moves-21.8-higher-tale-of-the-tape-2014-05-12", "https://www.nasdaq.com/articles/illumina-upgraded-to-strong-buy-analyst-blog-2014-05-12", "https://www.nasdaq.com/articles/xoma-posts-wider-q1-loss-analyst-blog-2014-05-09", "https://www.nasdaq.com/articles/q1-loss-wider-than-expected-at-genomic-health-analyst-blog-2014-05-09", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-thursday-tale-of-the-tape-2014-05-08", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-cepheid-view-tweaked-analyst-blog-2014-04-21", "https://www.nasdaq.com/articles/transition-therapeutics-tthi-jumps%3A-stock-up-11.5-tale-of-the-tape-2014-04-17", "https://www.nasdaq.com/articles/radnet-touches-new-52-week-high-analyst-blog-2014-05-12", "https://www.nasdaq.com/articles/kythera-biopharmaceuticals-inc.-kyth-in-focus%3A-stock-surges-9.9-tale-of-the-tape-2014-04", "https://www.nasdaq.com/articles/rite-aid-rad-jumps%3A-stock-up-8.4-tale-of-the-tape-2014-04-11", "https://www.nasdaq.com/articles/gilead-sciences-gild-falls%3A-stock-goes-down-7.3-tale-of-the-tape-2014-04-11", "https://www.nasdaq.com/articles/celladon-cldn-jumps%3A-stock-up-11.5-tale-of-the-tape-2014-04-11", "https://www.nasdaq.com/articles/baxano-surgical-inc.-baxs-in-focus%3A-stock-up-10.7-tale-of-the-tape-2014-04-11", "https://www.nasdaq.com/articles/qiagen-expands-personalized-healthcare-pipeline-analyst-blog-2014-04-11", "https://www.nasdaq.com/articles/radnet-touches-new-52-week-high-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/immunogen-inc.-imgn-in-focus%3A-stock-rallies-11-tale-of-the-tape-2014-04-17", "https://www.nasdaq.com/articles/kythera-biopharmaceuticals-inc.-kyth-in-focus%3A-stock-surges-9.9-tale-of-the-tape-2014-04", "https://www.nasdaq.com/articles/questcor-pharmaceuticals-qcor-shows-strength%3A-stock-surges-18.7-in-session-tale-of-the", "https://www.nasdaq.com/articles/response-genetics-rgdx-in-focus%3A-stock-up-18.3-tale-of-the-tape-2014-04-04", "https://www.nasdaq.com/articles/acceleron-pharma-xlrn-jumps%3A-stock-up-13.2-tale-of-the-tape-2014-04-03", "https://www.nasdaq.com/articles/exact-sciences-exas-jumps%3A-stock-adds-10.2-in-session-tale-of-the-tape-2014-04-01", "https://www.nasdaq.com/articles/insmed-incorporated-saw-its-shares-rise-more-than-7-in-the-session.-tale-of-the-tape-2014", "https://www.nasdaq.com/articles/integra-lifesciences-introduces-wound-matrix-analyst-blog-2014-03-28", "https://www.nasdaq.com/articles/idenix-pharmaceuticals-idix-jumps%3A-stock-up-12.4-tale-of-the-tape-2014-04-08", "https://www.nasdaq.com/articles/puma-biotechnology-pbyi-in-focus%3A-stock-tumbles-18.3-tale-of-the-tape-2014-04-08", "https://www.nasdaq.com/articles/what-falling-estimates-price-mean-for-kythera-kyth-tale-of-the-tape-2014-03-26", "https://www.nasdaq.com/articles/biogens-alprolix-approved-in-canada-analyst-blog-2014-03-24", "https://www.nasdaq.com/articles/strength-seen-in-ziopharm-oncology-ziop%3A-stock-up-11.8-tale-of-the-tape-2014-03-21", "https://www.nasdaq.com/articles/oncolytics-biotech-oncy-jumps%3A-stock-rises-5-tale-of-the-tape-2014-03-21", "https://www.nasdaq.com/articles/qiagens-quantiferon-tb-test-now-in-china-analyst-blog-2014-03-21", "https://www.nasdaq.com/articles/prothena-prta-jumps%3A-stock-rises-27.5-tale-of-the-tape-2014-03-20", "https://www.nasdaq.com/articles/cvs-caremark-receives-fep-contract-analyst-blog-2014-03-28", "https://www.nasdaq.com/articles/china-cord-blood-corporation-co-soars%3A-stock-up-5.7-tale-of-the-tape-2014-03-27", "https://www.nasdaq.com/articles/horizon-pharma-hznp-jumps%3A-stock-rises-5.6-tale-of-the-tape-2014-03-18", "https://www.nasdaq.com/articles/five-prime-therapeutics-fprx-surges%3A-stock-moves-22.6-higher-tale-of-the-tape-2014-03-18", "https://www.nasdaq.com/articles/insmed-insm-looks-good%3A-stock-adds-5.9-in-session-tale-of-the-tape-2014-03-14", "https://www.nasdaq.com/articles/first-laminoplasty-implant-at-integra-analyst-blog-2014-03-14", "https://www.nasdaq.com/articles/can-the-uptrend-continue-for-ani-pharmaceuticals-anip-tale-of-the-tape-2014-03-11", "https://www.nasdaq.com/articles/surging-earnings-estimates-signal-good-news-for-ani-pharmaceuticals-anip-tale-of-the-tape", "https://www.nasdaq.com/articles/why-ani-pharmaceuticals-anip-has-a-bright-short-term-future-tale-of-the-tape-2014-03-20", "https://www.nasdaq.com/articles/company-news-for-december-30-2013-corporate-summary-2013-12-30", "https://www.nasdaq.com/articles/post-teva-deal-anip-shares-rise-analyst-blog-2013-12-30", "https://www.nasdaq.com/articles/tuesday-sector-leaders-biotechnology-drugs-2014-02-18"], "Content": []}